{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "5703a5ec",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from utils.io import load_object, save_object\n",
    "from utils.evaluation import calc_eval_metrics\n",
    "import ast\n",
    "from collections import Counter\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import colorcet as cc\n",
    "from statsmodels.stats.multitest import multipletests\n",
    "import scispacy\n",
    "import spacy\n",
    "from transformers import AutoTokenizer, AutoModelForTokenClassification, AutoModel\n",
    "import torch"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d5602369",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=======4=======\n",
      "If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\n",
      "{'cancer_type': ['breast carcinoma cancer', 'breast cancer'], 'biomarker': ['pr', 'her2', 'aromatase', 'cdk4', None, 'aromatase', 'hormone receptor', 'hr', 'human epidermal growth factor receptor 2', 'her2']}\n",
      "=======15=======\n",
      "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, one recommended therapy is prednisone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\n",
      "{'cancer_type': ['castration'], 'biomarker': ['bard1', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'cyp17', 'brca', 'brcam', 'mcrpc']}\n",
      "=======97=======\n",
      "If a patient with melanoma cancer has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\n",
      "{'cancer_type': ['melanoma cancer', 'melanoma'], 'biomarker': ['braf', 'v600k', 'mek', 'b-raf', 'braf', 'v600e', 'v600k']}\n",
      "=======101=======\n",
      "If a patient with unresectable or metastatic any solid tumor cancer has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\n",
      "{'cancer_type': ['solid tumor cancer', 'solid tumors'], 'biomarker': ['braf', 'mek', 'b-raf', 'braf v600e']}\n",
      "=======148=======\n",
      "If a patient with invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\n",
      "{'cancer_type': ['invasive', 'breast carcinoma cancer', 'breast cancer'], 'biomarker': ['her2', 'er', 'aromatase', 'pi3k', 'akt', 'mtor', 'hormone', 'her2']}\n",
      "=======159=======\n",
      "If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\n",
      "{'cancer_type': ['breast carcinoma cancer', 'breast cancer'], 'biomarker': ['pr', 'her2', 'er', 'estrogen receptor', 'cdk4', None, 'estrogen receptor', 'hr', 'her2']}\n",
      "=======207=======\n",
      "If a patient with acute myeloid leukemia cancer has idh1 p.r132l, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\n",
      "{'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['idh1', 'idh1', 'isocitrate dehydrogenase-1', 'idh1', 'idh1']}\n",
      "=======209=======\n",
      "If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with for the treatment of adult patients with relapsed or refractory aml. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\n",
      "{'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['idh1', 'idh1', 'isocitrate dehydrogenase-1', 'idh1', 'idh1']}\n",
      "=======265=======\n",
      "If a patient with advanced ovarian epithelial tumor cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\n",
      "{'cancer_type': ['ovarian epithelial tumor cancer', 'epithelial ovarian', 'primary', 'peritoneal cancer'], 'biomarker': ['brca2', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'brca', 'fda']}\n",
      "=======315=======\n",
      "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\n",
      "{'cancer_type': [], 'biomarker': ['bard1', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'hrr', 'mcrpc']}\n",
      "=======329=======\n",
      "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51b oncogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\n",
      "{'cancer_type': [], 'biomarker': ['rad51b', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'hrr', 'mcrpc']}\n",
      "=======337=======\n",
      "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\n",
      "{'cancer_type': ['prostate adenocarcinoma cancer'], 'biomarker': ['brca1', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'brca', 'brcam']}\n",
      "=======418=======\n",
      "If a patient with early invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\n",
      "{'cancer_type': ['early breast cancer'], 'biomarker': ['her2', 'her2', 'topoisomerase', 'thymidylate synthase', 'her2', 'her2', 'neu receptor', 'hyaluronidase', 'her2']}\n",
      "=======420=======\n",
      "If a patient with early invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\n",
      "{'cancer_type': ['early breast cancer'], 'biomarker': ['her2', 'her2', 'her2', 'topoisomerase', 'her2', 'neu receptor', 'hyaluronidase', 'her2']}\n",
      "=======459=======\n",
      "If a patient with high-grade serous fallopian tube cancer cancer has brca1 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\n",
      "{'cancer_type': ['high-grade serous fallopian tube cancer cancer', 'epithelial ovarian', 'primary', 'peritoneal cancer'], 'biomarker': ['brca1', 'parp', 'rubraca', 'poly (adp-ribose) polymerase', 'parp', 'brca']}\n",
      "=======520=======\n",
      "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek2 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\n",
      "{'cancer_type': [], 'biomarker': ['chek2', 'parp', 'poly (adp-ribose) polymerase', 'parp', 'hrr', 'mcrpc']}\n",
      "=======546=======\n",
      "If a patient with high-grade serous fallopian tube cancer cancer has folr1 positive, one recommended therapy is mirvetuximab soravtansine. therapy type: chemotherapy. therapy strategy: folate receptor-alpha inhibition. indication: elahere is a folate receptor alpha (frα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with fr-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. select patients for therapy based on an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf\n",
      "{'cancer_type': ['high-grade serous fallopian tube cancer cancer', 'platinum', 'fallopian tube', 'primary', 'peritoneal cancer'], 'biomarker': ['folr1', 'folate receptor-alpha', 'folate receptor alpha', 'frα', 'microtubule', 'fr-alpha']}\n",
      "=======574=======\n",
      "If a patient with oligodendroglioma cancer has idh2 p.r172g, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\n",
      "{'cancer_type': ['oligodendroglioma cancer', 'grade 2 astrocytoma', 'oligodendroglioma'], 'biomarker': ['idh2', 'idh1', None, 'isocitrate dehydrogenase-1', 'idh1', 'isocitrate dehydrogenase-2', 'idh2', 'idh1', 'idh2']}\n",
      "=======600=======\n",
      "If a patient with pancreatic adenocarcinoma cancer has v::nrg1, one recommended therapy is zenocutuzumab. therapy type: targeted therapy. therapy strategy: nrg1 inhibition. indication: bizengri is a bispecific her2- and her3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf\n",
      "{'cancer_type': ['pancreatic adenocarcinoma cancer', 'pancreatic adenocarcinoma'], 'biomarker': ['nrg1', 'nrg1', 'her2', 'her3', 'neuregulin 1', 'nrg1']}\n",
      "=======614=======\n",
      "If a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\n",
      "{'cancer_type': ['breast carcinoma cancer', 'breast cancer'], 'biomarker': ['pr', 'her2', 'cdk4 / 6', 'aromatase', 'aromatase', 'hormone receptor', 'hr', 'human epidermal growth factor receptor 2', 'her2']}\n"
     ]
    }
   ],
   "source": [
    "test_ind = split_ranges(len(_CONTEXT), 10, 20)\n",
    "for i, e in enumerate(_CONTEXT):\n",
    "    if i in test_ind:\n",
    "        print(f\"======={i}=======\")\n",
    "        print(e)\n",
    "        print(extract_entities(e, model, tokenizer))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e8332662",
   "metadata": {},
   "source": [
    "### Load MOAlamanc data and synthetic queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "fd965574",
   "metadata": {},
   "outputs": [],
   "source": [
    "old_moalmanac_db=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8a6fa71e",
   "metadata": {},
   "source": [
    "### Testing NER using scispacy on synthetic queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ada22487",
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_ner_bionlp13cg_md-0.5.4.tar.gz\n",
    "# !pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_ner_bc5cdr_md-0.5.4.tar.gz\n",
    "# !pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_core_sci_scibert-0.5.4.tar.gz"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2e7b76b7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/opt/conda/lib/python3.10/site-packages/spacy/language.py:2195: FutureWarning: Possible set union at position 6328\n",
      "  deserializers[\"tokenizer\"] = lambda p: self.tokenizer.from_disk(  # type: ignore[union-attr]\n"
     ]
    }
   ],
   "source": [
    "bionlp13cg_nlp = spacy.load(\"en_ner_bionlp13cg_md\")\n",
    "bc5cdr_nlp = spacy.load(\"en_ner_bc5cdr_md\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c0d168b9",
   "metadata": {},
   "outputs": [],
   "source": [
    "spacy_ner_bionlp13cg_entities=[]\n",
    "spacy_ner_bc5cdr_entities=[]\n",
    "# spacy_ner_scibert_entities=[]\n",
    "\n",
    "for i in range(len(synthetic_prompt_groundtruth_dict.keys())):\n",
    "    \n",
    "    text=list(synthetic_prompt_groundtruth_dict.keys())[i]\n",
    "    \n",
    "    doc=bionlp13cg_nlp(text)\n",
    "    spacy_ner_bionlp13cg_entities.append(doc.ents)\n",
    "    \n",
    "    doc=bc5cdr_nlp(text)\n",
    "    spacy_ner_bc5cdr_entities.append(doc.ents)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "0ebc0879",
   "metadata": {},
   "outputs": [],
   "source": [
    "ner_entities = pd.DataFrame(\n",
    "    {\"synthetic_queries\":synthetic_prompt_groundtruth_dict.keys(), \n",
    "     \"spacy_ner_bionlp13cg_entities\":spacy_ner_bionlp13cg_entities,\n",
    "     \"spacy_ner_bc5cdr_entities\":spacy_ner_bc5cdr_entities,\n",
    "     })"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "56e7d773",
   "metadata": {},
   "source": [
    "### Load BioBERT finetuned for NER "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "259221c8",
   "metadata": {},
   "source": [
    "Pre-trained Models (saved in `/mnt/disks/moa-llm/models`):\n",
    "- Ishan0612/biobert-ner-disease-ncbi (https://huggingface.co/Ishan0612/biobert-ner-disease-ncbi): extracts disease\n",
    "- judithrosell/BioNLP13CG_bioBERT_NER (https://huggingface.co/judithrosell/BioNLP13CG_bioBERT_NER): fine-tuned version of biobert v1.1\n",
    "- judithrosell/BioBERT_BioNLP13CG_NER_new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "953ce63a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# load pre-trained BioBERT model for NER\n",
    "model = AutoModelForTokenClassification.from_pretrained(\"judithrosell/BioBERT_BioNLP13CG_NER_new\")\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"judithrosell/BioBERT_BioNLP13CG_NER_new\")\n",
    "id2label = model.config.id2label"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "455819d9",
   "metadata": {},
   "source": [
    "### Define BioBERT NER function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9c0cf6dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# function to predict entities using BioBERT\n",
    "def ner_predict_entities(text, model, tokenizer):\n",
    "    inputs = tokenizer(text, return_tensors=\"pt\", truncation=True, padding=True)\n",
    "    \n",
    "    # predictions\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs)\n",
    "        logits = outputs.logits\n",
    "        predictions = torch.argmax(logits, axis=2)\n",
    "    \n",
    "    # convert predictions to labels \n",
    "    predicted_labels = [id2label[pred.item()] for pred in predictions[0]]\n",
    "    \n",
    "    # align predictions with original tokents\n",
    "    tokens = tokenizer.convert_ids_to_tokens(inputs[\"input_ids\"][0])\n",
    "    \n",
    "    # extract entities\n",
    "    entities = []\n",
    "    current_entity = None\n",
    "    for token, label in zip(tokens, predicted_labels):\n",
    "        # skip special tokents\n",
    "        if token in [tokenizer.cls_token, tokenizer.sep_token, tokenizer.pad_token]:\n",
    "            continue\n",
    "        \n",
    "        # handle subwords\n",
    "        if token.startswith(\"##\"):\n",
    "            if current_entity:\n",
    "                current_entity[\"text\"] += token[2:] # remove '##' prefix\n",
    "            continue\n",
    "        if label.startswith(\"B-\"):\n",
    "            if current_entity:\n",
    "                entities.append(current_entity)\n",
    "            entity_type = label[2:]  # remove B- prefix\n",
    "            current_entity = {\"type\": entity_type, \"text\": token}\n",
    "        elif label.startswith(\"I-\") and current_entity and current_entity[\"type\"] == label[2:]:\n",
    "            current_entity[\"text\"] += \" \" + token\n",
    "        elif label == \"O\":\n",
    "            if current_entity:\n",
    "                entities.append(current_entity)\n",
    "                current_entity = None\n",
    "                \n",
    "    # last entity\n",
    "    if current_entity:\n",
    "        entities.append(current_entity)\n",
    "    return entities"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "80e3cd7e",
   "metadata": {},
   "source": [
    "Testing on small samples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f69c889e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic, accelerated, or blast phase, what would be the suggested lines of treatment?\n",
      "[{'type': 'Cancer', 'text': 'chronic myelogenous leukemia'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BCR'}, {'type': 'Gene_or_gene_product', 'text': 'ABL1'}]\n"
     ]
    }
   ],
   "source": [
    "sample_text = list(synthetic_prompt_groundtruth_dict.keys())[0]\n",
    "entities = ner_predict_entities(sample_text, model, tokenizer)\n",
    "print(sample_text)\n",
    "print(entities)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "badbb47e",
   "metadata": {},
   "source": [
    "## Rule-based retrieval based on matching key features"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2163c21d",
   "metadata": {},
   "source": [
    "The goal is to retrieve and prerank relevant context chunks based on matching key features that are critical for treatment decision-making.\n",
    "\n",
    "The key features we will use are:\n",
    "- cancer type\n",
    "- biomarker"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d78b500a",
   "metadata": {},
   "source": [
    "Below is the context db generated from the latest release of moalamanc database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "13d6cd55",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "statement_id",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "approval_status",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "approval_org",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "description",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "indication",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_drug",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_approach",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_strategy",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "approval_url",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "publication_date",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "context",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "f4ef0852-3432-485a-942e-2cb29f4b4efe",
       "rows": [
        [
         "0",
         "0",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03"
        ],
        [
         "1",
         "1",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03"
        ],
        [
         "2",
         "2",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03"
        ],
        [
         "3",
         "3",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Anastrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03"
        ],
        [
         "4",
         "4",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Anastrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03"
        ]
       ],
       "shape": {
        "columns": 14,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>approval_status</th>\n",
       "      <th>approval_org</th>\n",
       "      <th>description</th>\n",
       "      <th>indication</th>\n",
       "      <th>cancer_type</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy_drug</th>\n",
       "      <th>therapy_approach</th>\n",
       "      <th>therapy_strategy</th>\n",
       "      <th>therapy_type</th>\n",
       "      <th>approval_url</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>context</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>HER2-negative [present], PR positive [present]</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]...</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['Aromatase inhibition', 'CDK4/6 inhibition']</td>\n",
       "      <td>['Hormone therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>HER2-negative [present], PR positive [present]</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['Aromatase inhibition', 'CDK4/6 inhibition']</td>\n",
       "      <td>['Hormone therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id      approval_status approval_org  \\\n",
       "0             0  Regulatory approval          fda   \n",
       "1             1  Regulatory approval          fda   \n",
       "2             2  Regulatory approval          fda   \n",
       "3             3  Regulatory approval          fda   \n",
       "4             4  Regulatory approval          fda   \n",
       "\n",
       "                                         description  \\\n",
       "0  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "1  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "2  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "3  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "4  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "\n",
       "                                          indication  \\\n",
       "0  Verzenio is a kinase inhibitor indicated in co...   \n",
       "1  Verzenio is a kinase inhibitor indicated in co...   \n",
       "2  Verzenio is a kinase inhibitor indicated in co...   \n",
       "3  Verzenio is a kinase inhibitor indicated in co...   \n",
       "4  Verzenio is a kinase inhibitor indicated in co...   \n",
       "\n",
       "                 cancer_type  \\\n",
       "0  Invasive Breast Carcinoma   \n",
       "1  Invasive Breast Carcinoma   \n",
       "2  Invasive Breast Carcinoma   \n",
       "3  Invasive Breast Carcinoma   \n",
       "4  Invasive Breast Carcinoma   \n",
       "\n",
       "                                           biomarker  \\\n",
       "0     ER positive [present], HER2-negative [present]   \n",
       "1     HER2-negative [present], PR positive [present]   \n",
       "2  ER positive [present], HER2-negative [present]...   \n",
       "3     ER positive [present], HER2-negative [present]   \n",
       "4     HER2-negative [present], PR positive [present]   \n",
       "\n",
       "                     therapy_drug     therapy_approach  \\\n",
       "0    ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "1    ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "2    ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "3  ['Anastrozole', 'Abemaciclib']  Combination therapy   \n",
       "4  ['Anastrozole', 'Abemaciclib']  Combination therapy   \n",
       "\n",
       "                                    therapy_strategy  \\\n",
       "0  ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "1  ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "2  ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "3      ['Aromatase inhibition', 'CDK4/6 inhibition']   \n",
       "4      ['Aromatase inhibition', 'CDK4/6 inhibition']   \n",
       "\n",
       "                              therapy_type  \\\n",
       "0  ['Targeted therapy', 'Hormone therapy']   \n",
       "1  ['Targeted therapy', 'Hormone therapy']   \n",
       "2  ['Targeted therapy', 'Hormone therapy']   \n",
       "3  ['Hormone therapy', 'Targeted therapy']   \n",
       "4  ['Hormone therapy', 'Targeted therapy']   \n",
       "\n",
       "                                        approval_url publication_date  \\\n",
       "0  https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "1  https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "2  https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "3  https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "4  https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "\n",
       "                                             context  \n",
       "0  Approval status: Regulatory approval (fda)\\nDe...  \n",
       "1  Approval status: Regulatory approval (fda)\\nDe...  \n",
       "2  Approval status: Regulatory approval (fda)\\nDe...  \n",
       "3  Approval status: Regulatory approval (fda)\\nDe...  \n",
       "4  Approval status: Regulatory approval (fda)\\nDe...  "
      ]
     },
     "execution_count": 362,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "moalmanac_new_draft = pd.read_csv(f\"{root_dir}/data/latest_db/moalmanac-draft.dereferenced.unique.context_db.csv\")\n",
    "moalmanac_new_draft.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d616877c",
   "metadata": {},
   "source": [
    "#### BioBERT NER extraction and standardization of moalmanac entities"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1d0cf92e",
   "metadata": {},
   "source": [
    "Here, I'm going to:\n",
    "- extract cleaned gene symbols using BioBERT NER extraction\n",
    "- if nothing is extracted by BioBERT, fallback to the original biomarker (e.g., broad genomic markers like dMMR and MSI-H are not recognized by BioBERT)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "7b6395bb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "def clean_biomarker(text):\n",
    "    txt = re.sub(r\"\\s*\\[.*?\\]\", \"\", text).strip()\n",
    "    txt = txt.strip().replace(' ', '').upper() #[\"v\", \"ALK\"], [\"PD - L1\"], [\"c-Met\"]\n",
    "    \n",
    "    #ignore if it's too short (e.g. 1 character long)\n",
    "    if len(txt) <= 1:\n",
    "        return None\n",
    "    return txt\n",
    "\n",
    "\n",
    "def db_extract_entities(db, cancer_col='cancer_type', biomarker_col='biomarker'):\n",
    "    entities_dict = {'cancer_type': [], 'biomarker': []}\n",
    "    \n",
    "    #append cancer type (pre-standardized)\n",
    "    entities_dict['cancer_type'].append(db[cancer_col])\n",
    "    \n",
    "    #extract gene names using biobert \n",
    "    b_list = ner_predict_entities(db[biomarker_col], model, tokenizer)\n",
    "    \n",
    "    #if nothing's been extracted, append the original biomarker\n",
    "    if not b_list:\n",
    "        entities_dict['biomarker'].append(clean_biomarker(db[biomarker_col]))\n",
    "    else:\n",
    "        for b in b_list:\n",
    "            #clean and standardize the extracted biomarker\n",
    "            cleaned = clean_biomarker(b['text'])\n",
    "            if cleaned is not None and cleaned not in entities_dict['biomarker']:\n",
    "                entities_dict['biomarker'].append(cleaned)\n",
    "                    \n",
    "    return entities_dict\n",
    "\n",
    "\n",
    "def db_standardize_entities(entities_dict): \n",
    "    entities_dict['cancer_type'] = [cancer.upper() for cancer in entities_dict['cancer_type']] #so that both cancer types and biomarkers are in upper case\n",
    "    return entities_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ecd7ba67",
   "metadata": {},
   "outputs": [],
   "source": [
    "#split ranges for testing on small batches\n",
    "import random\n",
    "import math\n",
    "\n",
    "def split_ranges(max_int, num_ranges, samples=None):\n",
    "    step = math.ceil(max_int / num_ranges)\n",
    "    ranges = [(i*step+1, min((i+1)*step, max_int)) for i in range(num_ranges)]\n",
    "    \n",
    "    if samples is None:\n",
    "        return ranges\n",
    "    \n",
    "    # split samples evenly across ranges\n",
    "    n_per_range = samples // num_ranges\n",
    "    remainder = samples % num_ranges\n",
    "    \n",
    "    result = []\n",
    "    for i, r in enumerate(ranges):\n",
    "        count = n_per_range + (1 if i < remainder else 0)\n",
    "        result.extend(random.randint(r[0], r[1]) for _ in range(count))\n",
    "    \n",
    "    return result\n",
    "\n",
    "test_idx_list = split_ranges(moalmanac_new_draft.shape[0], 10, 50)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a6c74435",
   "metadata": {},
   "source": [
    "Run on all moalmanac entities (old)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f2652705",
   "metadata": {},
   "outputs": [],
   "source": [
    "for idx, row in old_moalmanac_db.iterrows():\n",
    "    entities_dict = db_extract_entities(row)\n",
    "    old_moalmanac_db.at[idx, 'entities_dict'] = json.dumps(entities_dict)\n",
    "    standardized_entities_dict = db_standardize_entities(entities_dict)\n",
    "    old_moalmanac_db.at[idx, 'standardized_entities_dict'] = json.dumps(standardized_entities_dict)\n",
    "    \n",
    "    print(idx)\n",
    "    print(row['cancer_type'])\n",
    "    print(row['biomarker'])\n",
    "    print(standardized_entities_dict)\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2e5320e0",
   "metadata": {},
   "source": [
    "Run on all moalmanac entities (new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 415,
   "id": "7079c87d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "1\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "2\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "3\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "4\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "5\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "6\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "7\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "8\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "9\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "10\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "11\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "12\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "13\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "14\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "15\n",
      "Prostate Adenocarcinoma\n",
      "BARD1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BARD1']}\n",
      "16\n",
      "Prostate Adenocarcinoma\n",
      "BRIP1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRIP1']}\n",
      "17\n",
      "Prostate Adenocarcinoma\n",
      "BRIP1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRIP1']}\n",
      "18\n",
      "Prostate Adenocarcinoma\n",
      "CDK12 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CDK12']}\n",
      "19\n",
      "Non-Small Cell Lung Cancer\n",
      "KRAS p.G12C [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['KRAS']}\n",
      "20\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "21\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR somatic variants [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "22\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "23\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PIK3CA']}\n",
      "24\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PIK3CA']}\n",
      "25\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PIK3CA']}\n",
      "26\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 20 (Insertion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "27\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 20 (Insertion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "28\n",
      "APL with PML-RARA\n",
      "PML::RARA [present]\n",
      "{'cancer_type': ['APL WITH PML-RARA'], 'biomarker': ['PML', 'RARA']}\n",
      "29\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "30\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present], ABL1 p.T315I [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "31\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 1% [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1']}\n",
      "32\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 50% [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1']}\n",
      "33\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 10% TIIC [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1', 'TIIC']}\n",
      "34\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "35\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "36\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR somatic variants [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "37\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "38\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "39\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "40\n",
      "Gastrointestinal Stromal Tumor\n",
      "PDGFRA p.D842V [present]\n",
      "{'cancer_type': ['GASTROINTESTINAL STROMAL TUMOR'], 'biomarker': ['PDGFRA']}\n",
      "41\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "42\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "43\n",
      "Non-Small Cell Lung Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['BRAF']}\n",
      "44\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "45\n",
      "Acute Lymphoid Leukemia\n",
      "CD19 + [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['CD19']}\n",
      "46\n",
      "Acute Lymphoid Leukemia\n",
      "CD19 + [present], BCR::ABL1 [not present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['CD19', 'BCR', 'ABL1']}\n",
      "47\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "48\n",
      "Anaplastic Large Cell Lymphoma\n",
      "CD30 + [present]\n",
      "{'cancer_type': ['ANAPLASTIC LARGE CELL LYMPHOMA'], 'biomarker': ['CD30']}\n",
      "49\n",
      "Anaplastic Large Cell Lymphoma\n",
      "CD30 + [present]\n",
      "{'cancer_type': ['ANAPLASTIC LARGE CELL LYMPHOMA'], 'biomarker': ['CD30']}\n",
      "50\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "51\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2']}\n",
      "52\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PIK3CA']}\n",
      "53\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PIK3CA']}\n",
      "54\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PIK3CA']}\n",
      "55\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], AKT1 somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'AKT1']}\n",
      "56\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], AKT1 somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'AKT1']}\n",
      "57\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], AKT1 somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'AKT1']}\n",
      "58\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], AKT1 amplification [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'AKT1']}\n",
      "59\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], AKT1 amplification [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'AKT1']}\n",
      "60\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], AKT1 amplification [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'AKT1']}\n",
      "61\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PTEN nonsense variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PTEN']}\n",
      "62\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PTEN nonsense variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PTEN']}\n",
      "63\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PTEN nonsense variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PTEN']}\n",
      "64\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PTEN frameshift variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PTEN']}\n",
      "65\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PTEN frameshift variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PTEN']}\n",
      "66\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PTEN frameshift variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PTEN']}\n",
      "67\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PTEN splice site variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PTEN']}\n",
      "68\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PTEN splice site variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PTEN']}\n",
      "69\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PTEN splice site variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PTEN']}\n",
      "70\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PTEN deletion [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PTEN']}\n",
      "71\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PTEN deletion [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PTEN']}\n",
      "72\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PTEN deletion [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PTEN']}\n",
      "73\n",
      "Non-Small Cell Lung Cancer\n",
      "MET Exon 14 (Splice Site) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['MET']}\n",
      "74\n",
      "Non-Small Cell Lung Cancer\n",
      "MET Exon 14 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['MET']}\n",
      "75\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present], Wild type ROS1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR', 'ROS1']}\n",
      "76\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present], dMMR [present], PD-L1 >= 50% [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR', 'DMMR', 'PD-L1']}\n",
      "77\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "78\n",
      "Colorectal Adenocarcinoma\n",
      "EGFR positive [present], Wild type KRAS [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['EGFR', 'KRAS']}\n",
      "79\n",
      "Colorectal Adenocarcinoma\n",
      "EGFR positive [present], Wild type KRAS [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['EGFR', 'KRAS']}\n",
      "80\n",
      "Colorectal Adenocarcinoma\n",
      "EGFR positive [present], Wild type KRAS [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['EGFR', 'KRAS']}\n",
      "81\n",
      "Colorectal Adenocarcinoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['BRAF']}\n",
      "82\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "83\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "84\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "85\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ROS1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ROS1']}\n",
      "86\n",
      "Anaplastic Large Cell Lymphoma\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['ANAPLASTIC LARGE CELL LYMPHOMA'], 'biomarker': ['ALK']}\n",
      "87\n",
      "Inflammatory Myofibroblastic Tumor\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['INFLAMMATORY MYOFIBROBLASTIC TUMOR'], 'biomarker': ['ALK']}\n",
      "88\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "89\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "90\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "91\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "92\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "93\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "94\n",
      "Non-Small Cell Lung Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['BRAF']}\n",
      "95\n",
      "Anaplastic Thyroid Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['ANAPLASTIC THYROID CANCER'], 'biomarker': ['BRAF']}\n",
      "96\n",
      "Any solid tumor\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['BRAF']}\n",
      "97\n",
      "Low-Grade Glioma, NOS\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['BRAF']}\n",
      "98\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "99\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "100\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "101\n",
      "Chronic Myeloid Leukemia, BCR-ABL1+\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'], 'biomarker': ['BCR', 'ABL1']}\n",
      "102\n",
      "Acute Lymphoid Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "103\n",
      "Endometrial Carcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['DMMR']}\n",
      "104\n",
      "Endometrial Carcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "105\n",
      "Endometrial Carcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['DMMR']}\n",
      "106\n",
      "Any solid tumor\n",
      "dMMR [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['DMMR']}\n",
      "107\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "108\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "109\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "110\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "111\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "112\n",
      "Endometrial Carcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['DMMR']}\n",
      "113\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], ESR1 oncogenic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'ESR1']}\n",
      "114\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R140Q [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "115\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R140L [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "116\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R140G [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "117\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R140W [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "118\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R172K [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "119\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R172M [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "120\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R172G [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "121\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R172S [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "122\n",
      "Acute Myeloid Leukemia\n",
      "IDH2 p.R172W [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH2']}\n",
      "123\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "124\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "125\n",
      "Colorectal Adenocarcinoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['BRAF']}\n",
      "126\n",
      "Non-Small Cell Lung Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['BRAF']}\n",
      "127\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ROS1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ROS1']}\n",
      "128\n",
      "Any solid tumor\n",
      "v::NTRK1 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK1']}\n",
      "129\n",
      "Any solid tumor\n",
      "v::NTRK2 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK2']}\n",
      "130\n",
      "Any solid tumor\n",
      "v::NTRK3 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK3']}\n",
      "131\n",
      "Bladder Urothelial Carcinoma\n",
      "FGFR3 p.R248C [present]\n",
      "{'cancer_type': ['BLADDER UROTHELIAL CARCINOMA'], 'biomarker': ['FGFR3']}\n",
      "132\n",
      "Bladder Urothelial Carcinoma\n",
      "FGFR3 p.S249C [present]\n",
      "{'cancer_type': ['BLADDER UROTHELIAL CARCINOMA'], 'biomarker': ['FGFR3']}\n",
      "133\n",
      "Bladder Urothelial Carcinoma\n",
      "FGFR3 p.G370C [present]\n",
      "{'cancer_type': ['BLADDER UROTHELIAL CARCINOMA'], 'biomarker': ['FGFR3']}\n",
      "134\n",
      "Bladder Urothelial Carcinoma\n",
      "FGFR3 p.Y373C [present]\n",
      "{'cancer_type': ['BLADDER UROTHELIAL CARCINOMA'], 'biomarker': ['FGFR3']}\n",
      "135\n",
      "Bladder Urothelial Carcinoma\n",
      "FGFR3::TACC3 [present]\n",
      "{'cancer_type': ['BLADDER UROTHELIAL CARCINOMA'], 'biomarker': ['FGFR3', 'TACC3']}\n",
      "136\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "137\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "138\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "139\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "140\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "141\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "142\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "143\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "144\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER']}\n",
      "145\n",
      "Invasive Breast Carcinoma\n",
      "PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['PR']}\n",
      "146\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'PR']}\n",
      "147\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "148\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "149\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "150\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "151\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "152\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "153\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "154\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "155\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "156\n",
      "Intrahepatic Cholangiocarcinoma\n",
      "FGFR2::v [present]\n",
      "{'cancer_type': ['INTRAHEPATIC CHOLANGIOCARCINOMA'], 'biomarker': ['FGFR2']}\n",
      "157\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "158\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "159\n",
      "Acute Lymphoid Leukemia\n",
      "CD33 + [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['CD33']}\n",
      "160\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3-ITD [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "161\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835Y [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "162\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835A [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "163\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835E [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "164\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835H [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "165\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835N [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "166\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835S [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "167\n",
      "Acute Lymphoid Leukemia\n",
      "FLT3 p.D835V [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "168\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "169\n",
      "Chronic Myeloid Leukemia, BCR-ABL1+\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'], 'biomarker': ['BCR', 'ABL1']}\n",
      "170\n",
      "Acute Lymphoid Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "171\n",
      "Myelodysplastic Syndromes\n",
      "PDGFRA rearrangements [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['PDGFRA']}\n",
      "172\n",
      "Myelodysplastic Syndromes\n",
      "PDGFRB rearrangements [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['PDGFRB']}\n",
      "173\n",
      "Aggressive Systemic Mastocytosis\n",
      "KIT p.D816V [not present]\n",
      "{'cancer_type': ['AGGRESSIVE SYSTEMIC MASTOCYTOSIS'], 'biomarker': ['KIT']}\n",
      "174\n",
      "Chronic Eosinophilic Leukemia, NOS\n",
      "FIP1L1::PDGFRA [present]\n",
      "{'cancer_type': ['CHRONIC EOSINOPHILIC LEUKEMIA, NOS'], 'biomarker': ['FIP1L1', 'PDGFRA']}\n",
      "175\n",
      "Gastrointestinal Stromal Tumor\n",
      "CD117 + [present]\n",
      "{'cancer_type': ['GASTROINTESTINAL STROMAL TUMOR'], 'biomarker': ['CD117']}\n",
      "176\n",
      "Gastrointestinal Stromal Tumor\n",
      "FIP1L1::PDGFRA [present]\n",
      "{'cancer_type': ['GASTROINTESTINAL STROMAL TUMOR'], 'biomarker': ['FIP1L1', 'PDGFRA']}\n",
      "177\n",
      "Cholangiocarcinoma\n",
      "FGFR2::v [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['FGFR2']}\n",
      "178\n",
      "Acute Lymphoid Leukemia\n",
      "CD22 + [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['CD22']}\n",
      "179\n",
      "Colorectal Adenocarcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "180\n",
      "Colorectal Adenocarcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['DMMR']}\n",
      "181\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 1% [present], Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1', 'ALK', 'EGFR']}\n",
      "182\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "183\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "184\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "185\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "186\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "187\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "188\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "189\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "190\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "191\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "192\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "193\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "194\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "195\n",
      "Myelodysplastic Syndromes\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['IDH1']}\n",
      "196\n",
      "Myelodysplastic Syndromes\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['IDH1']}\n",
      "197\n",
      "Myelodysplastic Syndromes\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['IDH1']}\n",
      "198\n",
      "Myelodysplastic Syndromes\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['IDH1']}\n",
      "199\n",
      "Myelodysplastic Syndromes\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['IDH1']}\n",
      "200\n",
      "Cholangiocarcinoma\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['IDH1']}\n",
      "201\n",
      "Cholangiocarcinoma\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['IDH1']}\n",
      "202\n",
      "Cholangiocarcinoma\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['IDH1']}\n",
      "203\n",
      "Cholangiocarcinoma\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['IDH1']}\n",
      "204\n",
      "Cholangiocarcinoma\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['IDH1']}\n",
      "205\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "206\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "207\n",
      "Invasive Breast Carcinoma\n",
      "PR positive [present], HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['PR', 'HER2']}\n",
      "208\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], PR positive [present], HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'PR', 'HER2']}\n",
      "209\n",
      "Any solid tumor\n",
      "v::NTRK1 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK1']}\n",
      "210\n",
      "Any solid tumor\n",
      "v::NTRK2 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK2']}\n",
      "211\n",
      "Any solid tumor\n",
      "v::NTRK3 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK3']}\n",
      "212\n",
      "Myelodysplastic Syndromes\n",
      "5q deletion [present]\n",
      "{'cancer_type': ['MYELODYSPLASTIC SYNDROMES'], 'biomarker': ['5QDELETION']}\n",
      "213\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "214\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "215\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "216\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "217\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "218\n",
      "Acute Myeloid Leukemia\n",
      "FLT3-ITD [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "219\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835Y [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "220\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835A [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "221\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835E [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "222\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835H [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "223\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835N [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "224\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835S [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "225\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.D835V [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "226\n",
      "Acute Myeloid Leukemia\n",
      "FLT3 p.I836del [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['FLT3']}\n",
      "227\n",
      "Acute Myeloid Leukemia\n",
      "CDK12 oncogenic variants [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['CDK12']}\n",
      "228\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 20 (Insertion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "229\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "230\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "231\n",
      "Chronic Myelogenous Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "232\n",
      "Chronic Myeloid Leukemia, BCR-ABL1+\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'], 'biomarker': ['BCR', 'ABL1']}\n",
      "233\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "234\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "235\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "236\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "237\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "238\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "239\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "240\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 1% [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1']}\n",
      "241\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "242\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "243\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "244\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "245\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "246\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "247\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "248\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "249\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "250\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "251\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "252\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "253\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "254\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "255\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "256\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "257\n",
      "Ovarian Epithelial Tumor\n",
      "HRD [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['HRD']}\n",
      "258\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "259\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "260\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "261\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "262\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "HRD [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['HRD']}\n",
      "263\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "264\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "265\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "266\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "267\n",
      "Peritoneal Serous Carcinoma\n",
      "HRD [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['HRD']}\n",
      "268\n",
      "Invasive Breast Carcinoma\n",
      "BRCA1 pathogenic variants [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['BRCA1', 'HER2']}\n",
      "269\n",
      "Invasive Breast Carcinoma\n",
      "BRCA2 pathogenic variants [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['BRCA2', 'HER2']}\n",
      "270\n",
      "Pancreatic Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PANCREATIC ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "271\n",
      "Pancreatic Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PANCREATIC ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "272\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "273\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "274\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "275\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "276\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "277\n",
      "Prostate Adenocarcinoma\n",
      "ATM pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATM']}\n",
      "278\n",
      "Prostate Adenocarcinoma\n",
      "ATM oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATM']}\n",
      "279\n",
      "Prostate Adenocarcinoma\n",
      "BARD1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BARD1']}\n",
      "280\n",
      "Prostate Adenocarcinoma\n",
      "BARD1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BARD1']}\n",
      "281\n",
      "Prostate Adenocarcinoma\n",
      "BRIP1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRIP1']}\n",
      "282\n",
      "Prostate Adenocarcinoma\n",
      "BRIP1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRIP1']}\n",
      "283\n",
      "Prostate Adenocarcinoma\n",
      "CDK12 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CDK12']}\n",
      "284\n",
      "Prostate Adenocarcinoma\n",
      "CDK12 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CDK12']}\n",
      "285\n",
      "Prostate Adenocarcinoma\n",
      "CHEK1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK1']}\n",
      "286\n",
      "Prostate Adenocarcinoma\n",
      "CHEK1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK1']}\n",
      "287\n",
      "Prostate Adenocarcinoma\n",
      "CHEK2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK2']}\n",
      "288\n",
      "Prostate Adenocarcinoma\n",
      "CHEK2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK2']}\n",
      "289\n",
      "Prostate Adenocarcinoma\n",
      "FANCL pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['FANCL']}\n",
      "290\n",
      "Prostate Adenocarcinoma\n",
      "FANCL oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['FANCL']}\n",
      "291\n",
      "Prostate Adenocarcinoma\n",
      "PALB2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['PALB2']}\n",
      "292\n",
      "Prostate Adenocarcinoma\n",
      "PALB2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['PALB2']}\n",
      "293\n",
      "Prostate Adenocarcinoma\n",
      "RAD51B pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51B']}\n",
      "294\n",
      "Prostate Adenocarcinoma\n",
      "RAD51B oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51B']}\n",
      "295\n",
      "Prostate Adenocarcinoma\n",
      "RAD51C pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51C']}\n",
      "296\n",
      "Prostate Adenocarcinoma\n",
      "RAD51C oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51C']}\n",
      "297\n",
      "Prostate Adenocarcinoma\n",
      "RAD51D pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51D']}\n",
      "298\n",
      "Prostate Adenocarcinoma\n",
      "RAD51D oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51D']}\n",
      "299\n",
      "Prostate Adenocarcinoma\n",
      "RAD54L pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD54L']}\n",
      "300\n",
      "Prostate Adenocarcinoma\n",
      "RAD54L oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD54L']}\n",
      "301\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "302\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "303\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "304\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "305\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "306\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "307\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "308\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "309\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "310\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "311\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "312\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "313\n",
      "Acute Myeloid Leukemia\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "314\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "315\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "316\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "317\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "318\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "319\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "320\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.T790M [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "321\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "322\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "323\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "324\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "325\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "326\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "327\n",
      "Colorectal Adenocarcinoma\n",
      "Wild type KRAS [present], Wild type HRAS [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['KRAS', 'HRAS']}\n",
      "328\n",
      "Colorectal Adenocarcinoma\n",
      "Wild type KRAS [present], Wild type HRAS [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['KRAS', 'HRAS']}\n",
      "329\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "330\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "331\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 1% [present], Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1', 'ALK', 'EGFR']}\n",
      "332\n",
      "Non-Small Cell Lung Cancer\n",
      "PD-L1 >= 1% [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['PD-L1']}\n",
      "333\n",
      "Head and Neck Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['HEAD AND NECK SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "334\n",
      "Any solid tumor\n",
      "dMMR [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['DMMR']}\n",
      "335\n",
      "Any solid tumor\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['MSI-H']}\n",
      "336\n",
      "Colorectal Adenocarcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['DMMR']}\n",
      "337\n",
      "Colorectal Adenocarcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "338\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-positive [present], PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2', 'PD-L1']}\n",
      "339\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-positive [present], PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2', 'PD-L1']}\n",
      "340\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-negative [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2']}\n",
      "341\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-negative [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2']}\n",
      "342\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "PD-L1 (CPS) >= 10 [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "343\n",
      "Esophageal Adenocarcinoma\n",
      "PD-L1 (CPS) >= 10 [present]\n",
      "{'cancer_type': ['ESOPHAGEAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "344\n",
      "Cervical Adenocarcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "345\n",
      "Cervical Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "346\n",
      "Cervical Adenocarcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "347\n",
      "Cervical Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "348\n",
      "Cervical Adenocarcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "349\n",
      "Cervical Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "350\n",
      "Cervical Adenocarcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "351\n",
      "Cervical Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "352\n",
      "Cervical Adenocarcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL ADENOCARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "353\n",
      "Cervical Squamous Cell Carcinoma\n",
      "PD-L1 (CPS) >= 1 [present]\n",
      "{'cancer_type': ['CERVICAL SQUAMOUS CELL CARCINOMA'], 'biomarker': ['PD-L1', 'CPS']}\n",
      "354\n",
      "Endometrial Carcinoma\n",
      "MSI-L [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['MSI-L']}\n",
      "355\n",
      "Endometrial Carcinoma\n",
      "pMMR [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['PMMR']}\n",
      "356\n",
      "Endometrial Carcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['ENDOMETRIAL CARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "357\n",
      "Any solid tumor\n",
      "TMB-H (>= 10 mutations / Mb) [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['TMB-H']}\n",
      "358\n",
      "Invasive Breast Carcinoma\n",
      "ER negative [present], HER2-negative [present], PR negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "359\n",
      "Invasive Breast Carcinoma\n",
      "PD-L1 (CPS) >= 10 [present], ER negative [present], HER2-negative [present], PR negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['PD-L1', 'ER', 'HER2', 'PR']}\n",
      "360\n",
      "Invasive Breast Carcinoma\n",
      "PD-L1 (CPS) >= 10 [present], ER negative [present], HER2-negative [present], PR negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['PD-L1', 'ER', 'HER2', 'PR']}\n",
      "361\n",
      "Cholangiocarcinoma\n",
      "FGFR2::v [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['FGFR2']}\n",
      "362\n",
      "Cholangiocarcinoma\n",
      "FGFR2 rearrangements [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['FGFR2']}\n",
      "363\n",
      "Myeloid/Lymphoid Neoplasms\n",
      "FGFR1 rearrangements [present]\n",
      "{'cancer_type': ['MYELOID/LYMPHOID NEOPLASMS'], 'biomarker': ['FGFR1']}\n",
      "364\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "365\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "366\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "367\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "368\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "369\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "370\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "371\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "372\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "373\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "374\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "375\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "376\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "377\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "378\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "379\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "380\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "381\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "382\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "383\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "384\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "385\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "386\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "387\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "388\n",
      "Acute Lymphoid Leukemia\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "389\n",
      "Acute Lymphoid Leukemia\n",
      "ABL1 p.T315I [present], BCR::ABL1 [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['ABL1', 'BCR']}\n",
      "390\n",
      "Chronic Myelogenous Leukemia\n",
      "ABL1 p.T315I [present]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['ABL1']}\n",
      "391\n",
      "Non-Small Cell Lung Cancer\n",
      "v::RET [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['V::RET']}\n",
      "392\n",
      "Papillary Thyroid Cancer\n",
      "v::RET [present]\n",
      "{'cancer_type': ['PAPILLARY THYROID CANCER'], 'biomarker': ['V::RET']}\n",
      "393\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "394\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "395\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ROS1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ROS1']}\n",
      "396\n",
      "Any solid tumor\n",
      "v::NTRK1 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK1']}\n",
      "397\n",
      "Any solid tumor\n",
      "v::NTRK2 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK2']}\n",
      "398\n",
      "Any solid tumor\n",
      "v::NTRK3 [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['NTRK3']}\n",
      "399\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "400\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "401\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "402\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "403\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "404\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "405\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "406\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "407\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "408\n",
      "Non-Hodgkin Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['NON-HODGKIN LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "409\n",
      "Non-Hodgkin Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['NON-HODGKIN LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "410\n",
      "Non-Hodgkin Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['NON-HODGKIN LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "411\n",
      "Non-Hodgkin Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['NON-HODGKIN LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "412\n",
      "Non-Hodgkin Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['NON-HODGKIN LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "413\n",
      "Diffuse Large B-Cell Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['DIFFUSE LARGE B-CELL LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "414\n",
      "Burkitt Lymphoma\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['BURKITT LYMPHOMA'], 'biomarker': ['CD20']}\n",
      "415\n",
      "Mature B-Cell Neoplasms\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['MATURE B-CELL NEOPLASMS'], 'biomarker': ['CD20']}\n",
      "416\n",
      "Chronic Lymphocytic Leukemia\n",
      "CD20 + [present]\n",
      "{'cancer_type': ['CHRONIC LYMPHOCYTIC LEUKEMIA'], 'biomarker': ['CD20']}\n",
      "417\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "418\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA1']}\n",
      "419\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "420\n",
      "Ovarian Epithelial Tumor\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['BRCA2']}\n",
      "421\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "422\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA1']}\n",
      "423\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "424\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['BRCA2']}\n",
      "425\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "426\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "427\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "428\n",
      "Peritoneal Serous Carcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "429\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "430\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "431\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "432\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "433\n",
      "Invasive Breast Carcinoma\n",
      "ER negative [present], HER2-negative [present], PR negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "434\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "435\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "436\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "437\n",
      "Non-Small Cell Lung Cancer\n",
      "v::RET [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['V::RET']}\n",
      "438\n",
      "Medullary Thyroid Cancer\n",
      "RET oncogenic variants [present]\n",
      "{'cancer_type': ['MEDULLARY THYROID CANCER'], 'biomarker': ['RET']}\n",
      "439\n",
      "Anaplastic Thyroid Cancer\n",
      "v::RET [present]\n",
      "{'cancer_type': ['ANAPLASTIC THYROID CANCER'], 'biomarker': ['V::RET']}\n",
      "440\n",
      "Any solid tumor\n",
      "v::RET [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['V::RET']}\n",
      "441\n",
      "Non-Small Cell Lung Cancer\n",
      "KRAS p.G12C [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['KRAS']}\n",
      "442\n",
      "Invasive Breast Carcinoma\n",
      "BRCA1 pathogenic variants [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['BRCA1', 'HER2']}\n",
      "443\n",
      "Invasive Breast Carcinoma\n",
      "BRCA2 pathogenic variants [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['BRCA2', 'HER2']}\n",
      "444\n",
      "Non-Small Cell Lung Cancer\n",
      "MET Exon 14 (Splice Site) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['MET']}\n",
      "445\n",
      "Non-Small Cell Lung Cancer\n",
      "MET Exon 14 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['MET']}\n",
      "446\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "447\n",
      "Melanoma\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "448\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "449\n",
      "Non-Small Cell Lung Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['BRAF']}\n",
      "450\n",
      "Anaplastic Thyroid Cancer\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['ANAPLASTIC THYROID CANCER'], 'biomarker': ['BRAF']}\n",
      "451\n",
      "Any solid tumor\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['BRAF']}\n",
      "452\n",
      "Low-Grade Glioma, NOS\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['BRAF']}\n",
      "453\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "454\n",
      "Gastrointestinal Stromal Tumor\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['GASTROINTESTINAL STROMAL TUMOR'], 'biomarker': ['HER2']}\n",
      "455\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "456\n",
      "Invasive Breast Carcinoma\n",
      "HER2-low [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "457\n",
      "Non-Small Cell Lung Cancer\n",
      "ERBB2 oncogenic variants [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ERBB2']}\n",
      "458\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2']}\n",
      "459\n",
      "Any solid tumor\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['ANY SOLID TUMOR'], 'biomarker': ['HER2']}\n",
      "460\n",
      "Invasive Breast Carcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2']}\n",
      "461\n",
      "Melanoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "462\n",
      "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['NON-LANGERHANS CELL HISTIOCYTOSIS/ERDHEIM-CHESTER DISEASE'], 'biomarker': ['BRAF']}\n",
      "463\n",
      "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['NON-LANGERHANS CELL HISTIOCYTOSIS/ERDHEIM-CHESTER DISEASE'], 'biomarker': ['BRAF']}\n",
      "464\n",
      "Follicular Lymphoma\n",
      "EZH2 p.Y646N [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "465\n",
      "Follicular Lymphoma\n",
      "EZH2 p.Y646F [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "466\n",
      "Follicular Lymphoma\n",
      "EZH2 p.Y646H [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "467\n",
      "Follicular Lymphoma\n",
      "EZH2 p.Y646S [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "468\n",
      "Follicular Lymphoma\n",
      "EZH2 p.Y646C [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "469\n",
      "Follicular Lymphoma\n",
      "EZH2 p.A862G [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "470\n",
      "Follicular Lymphoma\n",
      "EZH2 p.A692V [present]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "471\n",
      "Prostate Adenocarcinoma\n",
      "BRCA1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA1']}\n",
      "472\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "473\n",
      "Prostate Adenocarcinoma\n",
      "BRCA2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['BRCA2']}\n",
      "474\n",
      "Prostate Adenocarcinoma\n",
      "ATM pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATM']}\n",
      "475\n",
      "Prostate Adenocarcinoma\n",
      "ATM oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATM']}\n",
      "476\n",
      "Prostate Adenocarcinoma\n",
      "ATR oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATR']}\n",
      "477\n",
      "Prostate Adenocarcinoma\n",
      "CDK12 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CDK12']}\n",
      "478\n",
      "Prostate Adenocarcinoma\n",
      "ATR pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['ATR']}\n",
      "479\n",
      "Prostate Adenocarcinoma\n",
      "FANCA oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['FANCA']}\n",
      "480\n",
      "Prostate Adenocarcinoma\n",
      "CHEK2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK2']}\n",
      "481\n",
      "Prostate Adenocarcinoma\n",
      "CHEK2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CHEK2']}\n",
      "482\n",
      "Prostate Adenocarcinoma\n",
      "FANCA pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['FANCA']}\n",
      "483\n",
      "Prostate Adenocarcinoma\n",
      "MLH1 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['MLH1']}\n",
      "484\n",
      "Prostate Adenocarcinoma\n",
      "PALB2 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['PALB2']}\n",
      "485\n",
      "Prostate Adenocarcinoma\n",
      "PALB2 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['PALB2']}\n",
      "486\n",
      "Prostate Adenocarcinoma\n",
      "MLH1 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['MLH1']}\n",
      "487\n",
      "Prostate Adenocarcinoma\n",
      "MRE11 oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['MRE11']}\n",
      "488\n",
      "Prostate Adenocarcinoma\n",
      "RAD51C pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51C']}\n",
      "489\n",
      "Prostate Adenocarcinoma\n",
      "RAD51C oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['RAD51C']}\n",
      "490\n",
      "Prostate Adenocarcinoma\n",
      "MRE11 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['MRE11']}\n",
      "491\n",
      "Prostate Adenocarcinoma\n",
      "NBN oncogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['NBN']}\n",
      "492\n",
      "Prostate Adenocarcinoma\n",
      "NBN pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['NBN']}\n",
      "493\n",
      "Renal Angiomyolipoma\n",
      "TSC1 oncogenic variants [present]\n",
      "{'cancer_type': ['RENAL ANGIOMYOLIPOMA'], 'biomarker': ['TSC1']}\n",
      "494\n",
      "Renal Angiomyolipoma\n",
      "TSC2 oncogenic variants [present]\n",
      "{'cancer_type': ['RENAL ANGIOMYOLIPOMA'], 'biomarker': ['TSC2']}\n",
      "495\n",
      "Anaplastic Thyroid Cancer\n",
      "TSC1 oncogenic variants [present]\n",
      "{'cancer_type': ['ANAPLASTIC THYROID CANCER'], 'biomarker': ['TSC1']}\n",
      "496\n",
      "Anaplastic Thyroid Cancer\n",
      "TSC2 oncogenic variants [present]\n",
      "{'cancer_type': ['ANAPLASTIC THYROID CANCER'], 'biomarker': ['TSC2']}\n",
      "497\n",
      "Prostate Adenocarcinoma\n",
      "CDK12 pathogenic variants [present]\n",
      "{'cancer_type': ['PROSTATE ADENOCARCINOMA'], 'biomarker': ['CDK12']}\n",
      "498\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "499\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "500\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "501\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "502\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR Exon 19 (Deletion) [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "503\n",
      "Non-Small Cell Lung Cancer\n",
      "EGFR p.L858R [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "504\n",
      "Ovarian Epithelial Tumor\n",
      "FOLR1 positive [present]\n",
      "{'cancer_type': ['OVARIAN EPITHELIAL TUMOR'], 'biomarker': ['FOLR1']}\n",
      "505\n",
      "High-Grade Serous Fallopian Tube Cancer\n",
      "FOLR1 positive [present]\n",
      "{'cancer_type': ['HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER'], 'biomarker': ['FOLR1']}\n",
      "506\n",
      "Peritoneal Serous Carcinoma\n",
      "FOLR1 positive [present]\n",
      "{'cancer_type': ['PERITONEAL SEROUS CARCINOMA'], 'biomarker': ['FOLR1']}\n",
      "507\n",
      "Low-Grade Glioma, NOS\n",
      "BRAF rearrangements [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['BRAF']}\n",
      "508\n",
      "Low-Grade Glioma, NOS\n",
      "v::BRAF [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['V:', 'BRAF']}\n",
      "509\n",
      "Low-Grade Glioma, NOS\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['BRAF']}\n",
      "510\n",
      "Low-Grade Glioma, NOS\n",
      "BRAF p.V600K [present]\n",
      "{'cancer_type': ['LOW-GRADE GLIOMA, NOS'], 'biomarker': ['BRAF']}\n",
      "511\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "512\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "513\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "514\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "515\n",
      "Colorectal Adenocarcinoma\n",
      "KRAS p.G12C [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['KRAS']}\n",
      "516\n",
      "Astrocytoma\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH1']}\n",
      "517\n",
      "Astrocytoma\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH1']}\n",
      "518\n",
      "Astrocytoma\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH1']}\n",
      "519\n",
      "Astrocytoma\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH1']}\n",
      "520\n",
      "Astrocytoma\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH1']}\n",
      "521\n",
      "Astrocytoma\n",
      "IDH2 p.R172K [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH2']}\n",
      "522\n",
      "Astrocytoma\n",
      "IDH2 p.R172M [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH2']}\n",
      "523\n",
      "Astrocytoma\n",
      "IDH2 p.R172G [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH2']}\n",
      "524\n",
      "Astrocytoma\n",
      "IDH2 p.R172S [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH2']}\n",
      "525\n",
      "Astrocytoma\n",
      "IDH2 p.R172W [present]\n",
      "{'cancer_type': ['ASTROCYTOMA'], 'biomarker': ['IDH2']}\n",
      "526\n",
      "Oligodendroglioma\n",
      "IDH1 p.R132C [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH1']}\n",
      "527\n",
      "Oligodendroglioma\n",
      "IDH1 p.R132G [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH1']}\n",
      "528\n",
      "Oligodendroglioma\n",
      "IDH1 p.R132H [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH1']}\n",
      "529\n",
      "Oligodendroglioma\n",
      "IDH1 p.R132L [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH1']}\n",
      "530\n",
      "Oligodendroglioma\n",
      "IDH1 p.R132S [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH1']}\n",
      "531\n",
      "Oligodendroglioma\n",
      "IDH2 p.R172K [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH2']}\n",
      "532\n",
      "Oligodendroglioma\n",
      "IDH2 p.R172M [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH2']}\n",
      "533\n",
      "Oligodendroglioma\n",
      "IDH2 p.R172G [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH2']}\n",
      "534\n",
      "Oligodendroglioma\n",
      "IDH2 p.R172S [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH2']}\n",
      "535\n",
      "Oligodendroglioma\n",
      "IDH2 p.R172W [present]\n",
      "{'cancer_type': ['OLIGODENDROGLIOMA'], 'biomarker': ['IDH2']}\n",
      "536\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "537\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "538\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "539\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "540\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "541\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "542\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "543\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "544\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "545\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "546\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "547\n",
      "Colorectal Adenocarcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['DMMR']}\n",
      "548\n",
      "Colorectal Adenocarcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "549\n",
      "Colorectal Adenocarcinoma\n",
      "dMMR [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['DMMR']}\n",
      "550\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PIK3CA']}\n",
      "551\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR', 'PIK3CA']}\n",
      "552\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR', 'PIK3CA']}\n",
      "553\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-negative [present], CLDN18.2 >= 75% [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2', 'CLDN18.2']}\n",
      "554\n",
      "Adenocarcinoma of the Gastroesophageal Junction\n",
      "HER2-negative [present], CLDN18.2 >= 75% [present]\n",
      "{'cancer_type': ['ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION'], 'biomarker': ['HER2', 'CLDN18.2']}\n",
      "555\n",
      "Intraductal Papillary Neoplasm of the Bile Duct\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT'], 'biomarker': ['HER2']}\n",
      "556\n",
      "Intracholecystic Papillary Neoplasm\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['INTRACHOLECYSTIC PAPILLARY NEOPLASM'], 'biomarker': ['HER2']}\n",
      "557\n",
      "Cholangiocarcinoma\n",
      "HER2-positive [present]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['HER2']}\n",
      "558\n",
      "Non-Small Cell Lung Cancer\n",
      "v::NRG1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['NRG1']}\n",
      "559\n",
      "Pancreatic Adenocarcinoma\n",
      "v::NRG1 [present]\n",
      "{'cancer_type': ['PANCREATIC ADENOCARCINOMA'], 'biomarker': ['NRG1']}\n",
      "560\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ALK [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK']}\n",
      "561\n",
      "Colorectal Adenocarcinoma\n",
      "BRAF p.V600E [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['BRAF']}\n",
      "562\n",
      "Chronic Myeloid Leukemia, BCR-ABL1+\n",
      "BCR::ABL1 [present]\n",
      "{'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'], 'biomarker': ['BCR', 'ABL1']}\n",
      "563\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "564\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "565\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "566\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "567\n",
      "Non-Small Cell Lung Cancer\n",
      "Wild type ALK [present], Wild type EGFR [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ALK', 'EGFR']}\n",
      "568\n",
      "Acute Lymphoid Leukemia\n",
      "t(KMT2A;v) [present]\n",
      "{'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['KMT2A']}\n",
      "569\n",
      "Acute Myeloid Leukemia\n",
      "t(KMT2A;v) [present]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['KMT2A']}\n",
      "570\n",
      "Burkitt Lymphoma\n",
      "t(KMT2A;v) [present]\n",
      "{'cancer_type': ['BURKITT LYMPHOMA'], 'biomarker': ['KMT2A']}\n",
      "571\n",
      "Acute Leukemias of Ambiguous Lineage\n",
      "t(KMT2A;v) [present]\n",
      "{'cancer_type': ['ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE'], 'biomarker': ['KMT2A']}\n",
      "572\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "573\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "574\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "575\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "576\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2', 'PR']}\n",
      "577\n",
      "Invasive Breast Carcinoma\n",
      "ER positive [present], HER2-negative [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['ER', 'HER2']}\n",
      "578\n",
      "Invasive Breast Carcinoma\n",
      "HER2-negative [present], PR positive [present]\n",
      "{'cancer_type': ['INVASIVE BREAST CARCINOMA'], 'biomarker': ['HER2', 'PR']}\n",
      "579\n",
      "Colorectal Adenocarcinoma\n",
      "MSI-H [present]\n",
      "{'cancer_type': ['COLORECTAL ADENOCARCINOMA'], 'biomarker': ['MSI-H']}\n",
      "580\n",
      "Non-Small Cell Lung Cancer\n",
      "v::ROS1 [present]\n",
      "{'cancer_type': ['NON-SMALL CELL LUNG CANCER'], 'biomarker': ['ROS1']}\n",
      "581\n",
      "Lung Non-Squamous Non-Small Cell Carcinoma\n",
      "c-Met >= 50% [present]\n",
      "{'cancer_type': ['LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA'], 'biomarker': ['C-MET']}\n",
      "582\n",
      "Low-Grade Serous Ovarian Cancer\n",
      "KRAS p.G12C [present]\n",
      "{'cancer_type': ['LOW-GRADE SEROUS OVARIAN CANCER'], 'biomarker': ['KRAS']}\n",
      "583\n",
      "Low-Grade Serous Ovarian Cancer\n",
      "KRAS p.G12V [present]\n",
      "{'cancer_type': ['LOW-GRADE SEROUS OVARIAN CANCER'], 'biomarker': ['KRAS']}\n"
     ]
    }
   ],
   "source": [
    "for idx, row in moalmanac_new_draft.iterrows():\n",
    "    entities_dict = db_extract_entities(row)\n",
    "    moalmanac_new_draft.at[idx, 'entities_dict'] = json.dumps(entities_dict)\n",
    "    standardized_entities_dict = db_standardize_entities(entities_dict)\n",
    "    moalmanac_new_draft.at[idx, 'standardized_entities_dict'] = json.dumps(standardized_entities_dict)\n",
    "    \n",
    "    print(idx)\n",
    "    print(row['cancer_type'])\n",
    "    print(row['biomarker'])\n",
    "    print(standardized_entities_dict)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 416,
   "id": "6139456d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "statement_id",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "approval_status",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "approval_org",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "description",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "indication",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_drug",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_approach",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_strategy",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "approval_url",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "publication_date",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "context",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "entities_dict",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "standardized_entities_dict",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "8aa96999-7f67-4147-ba47-049cbc1b7a62",
       "rows": [
        [
         "0",
         "0",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\"]}"
        ],
        [
         "1",
         "1",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\"]}"
        ],
        [
         "2",
         "2",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Abemaciclib', 'Tamoxifen']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "3",
         "3",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Anastrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\"]}"
        ],
        [
         "4",
         "4",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Anastrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\"]}"
        ],
        [
         "5",
         "5",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Anastrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "6",
         "6",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Letrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\"]}"
        ],
        [
         "7",
         "7",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Letrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\"]}"
        ],
        [
         "8",
         "8",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
         "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Letrozole', 'Abemaciclib']",
         "Combination therapy",
         "['Aromatase inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "9",
         "9",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Fulvestrant', 'Abemaciclib']",
         "Combination therapy",
         "['Estrogen receptor inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nIndication: Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\"]}"
        ],
        [
         "10",
         "10",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Fulvestrant', 'Abemaciclib']",
         "Combination therapy",
         "['Estrogen receptor inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nIndication: Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\"]}"
        ],
        [
         "11",
         "11",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Fulvestrant', 'Abemaciclib']",
         "Combination therapy",
         "['Estrogen receptor inhibition', 'CDK4/6 inhibition']",
         "['Hormone therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nIndication: Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "12",
         "12",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present]",
         "['Abemaciclib']",
         "Monotherapy",
         "['CDK4/6 inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nIndication: Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\"]}"
        ],
        [
         "13",
         "13",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present]",
         "['Abemaciclib']",
         "Monotherapy",
         "['CDK4/6 inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nIndication: Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\"]}"
        ],
        [
         "14",
         "14",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Abemaciclib']",
         "Monotherapy",
         "['CDK4/6 inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nIndication: Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "15",
         "15",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
         "AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",
         "Prostate Adenocarcinoma",
         "BARD1 oncogenic variants [present]",
         "['Abiraterone acetate', 'Niraparib', 'Prednisone']",
         "Combination therapy",
         "['Antiandrogen', 'PARP inhibition', 'Corticosteroid']",
         "['Hormone therapy', 'Targeted therapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
         "2023-08-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nIndication: AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BARD1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
         "{\"cancer_type\": [\"Prostate Adenocarcinoma\"], \"biomarker\": [\"BARD1\"]}",
         "{\"cancer_type\": [\"PROSTATE ADENOCARCINOMA\"], \"biomarker\": [\"BARD1\"]}"
        ],
        [
         "16",
         "16",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
         "AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",
         "Prostate Adenocarcinoma",
         "BRIP1 oncogenic variants [present]",
         "['Abiraterone acetate', 'Niraparib', 'Prednisone']",
         "Combination therapy",
         "['Antiandrogen', 'PARP inhibition', 'Corticosteroid']",
         "['Hormone therapy', 'Targeted therapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
         "2023-08-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nIndication: AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
         "{\"cancer_type\": [\"Prostate Adenocarcinoma\"], \"biomarker\": [\"BRIP1\"]}",
         "{\"cancer_type\": [\"PROSTATE ADENOCARCINOMA\"], \"biomarker\": [\"BRIP1\"]}"
        ],
        [
         "17",
         "17",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
         "AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",
         "Prostate Adenocarcinoma",
         "BRIP1 pathogenic variants [present]",
         "['Abiraterone acetate', 'Niraparib', 'Prednisone']",
         "Combination therapy",
         "['Antiandrogen', 'PARP inhibition', 'Corticosteroid']",
         "['Hormone therapy', 'Targeted therapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
         "2023-08-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nIndication: AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 pathogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
         "{\"cancer_type\": [\"Prostate Adenocarcinoma\"], \"biomarker\": [\"BRIP1\"]}",
         "{\"cancer_type\": [\"PROSTATE ADENOCARCINOMA\"], \"biomarker\": [\"BRIP1\"]}"
        ],
        [
         "18",
         "18",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
         "AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",
         "Prostate Adenocarcinoma",
         "CDK12 pathogenic variants [present]",
         "['Abiraterone acetate', 'Niraparib', 'Prednisone']",
         "Combination therapy",
         "['Antiandrogen', 'PARP inhibition', 'Corticosteroid']",
         "['Hormone therapy', 'Targeted therapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
         "2023-08-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nIndication: AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 pathogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
         "{\"cancer_type\": [\"Prostate Adenocarcinoma\"], \"biomarker\": [\"CDK12\"]}",
         "{\"cancer_type\": [\"PROSTATE ADENOCARCINOMA\"], \"biomarker\": [\"CDK12\"]}"
        ],
        [
         "19",
         "19",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
         "KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
         "Non-Small Cell Lung Cancer",
         "KRAS p.G12C [present]",
         "['Adagrasib']",
         "Monotherapy",
         "['RAS inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf",
         "2022-12-12",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).\nIndication: KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: KRAS p.G12C [present]\nTherapy: Adagrasib\nTherapy approach: Monotherapy\nTherapy strategy: RAS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf\nPublication date: 2022-12-12",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"KRAS\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"KRAS\"]}"
        ],
        [
         "20",
         "20",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine",
         "KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.",
         "Invasive Breast Carcinoma",
         "HER2-positive [present]",
         "['Trastuzumab emtansine']",
         "Monotherapy",
         "['HER2 inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf",
         "2022-02-02",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine\nIndication: KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab emtansine\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf\nPublication date: 2022-02-02",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\"]}"
        ],
        [
         "21",
         "22",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.",
         "GILOTRIF is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test (1.1) Limitations of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations.",
         "Non-Small Cell Lung Cancer",
         "EGFR somatic variants [present]",
         "['Afatinib']",
         "Monotherapy",
         "['EGFR inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf",
         "2022-04-07",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.\nIndication: GILOTRIF is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test (1.1) Limitations of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR somatic variants [present]\nTherapy: Afatinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf\nPublication date: 2022-04-07",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"EGFR\"]}"
        ],
        [
         "22",
         "23",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.",
         "ALECENSA is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.",
         "Non-Small Cell Lung Cancer",
         "v::ALK [present]",
         "['Alectinib']",
         "Monotherapy",
         "['ALK inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf",
         "2024-04-18",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.\nIndication: ALECENSA is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Alectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf\nPublication date: 2024-04-18",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"ALK\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ALK\"]}"
        ],
        [
         "23",
         "25",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
         "PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]",
         "['Alpelisib', 'Fulvestrant']",
         "Combination therapy",
         "['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
         "2024-01-18",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nIndication: PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PIK3CA\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PIK3CA\"]}"
        ],
        [
         "24",
         "26",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
         "PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",
         "Invasive Breast Carcinoma",
         "HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]",
         "['Alpelisib', 'Fulvestrant']",
         "Combination therapy",
         "['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
         "2024-01-18",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nIndication: PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"HER2\", \"PR\", \"PIK3CA\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"HER2\", \"PR\", \"PIK3CA\"]}"
        ],
        [
         "25",
         "27",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
         "PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]",
         "['Alpelisib', 'Fulvestrant']",
         "Combination therapy",
         "['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
         "2024-01-18",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nIndication: PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\", \"PIK3CA\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\", \"PIK3CA\"]}"
        ],
        [
         "26",
         "28",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
         "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
         "Non-Small Cell Lung Cancer",
         "EGFR Exon 20 (Insertion) [present]",
         "['Carboplatin', 'Pemetrexed', 'Amivantamab']",
         "Combination therapy",
         "['Platinum-based chemotherapy', 'Antifolate', 'EGFR inhibition']",
         "['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
         "2024-09-19",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.\nIndication: RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 20 (Insertion) [present]\nTherapy: Carboplatin + Pemetrexed + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Antifolate + EGFR inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"EGFR\"]}"
        ],
        [
         "27",
         "29",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
         "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
         "Non-Small Cell Lung Cancer",
         "EGFR Exon 20 (Insertion) [present]",
         "['Amivantamab']",
         "Monotherapy",
         "['EGFR inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
         "2024-09-19",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.\nIndication: RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 20 (Insertion) [present]\nTherapy: Amivantamab\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"EGFR\"]}"
        ],
        [
         "28",
         "30",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
         "TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
         "APL with PML-RARA",
         "PML::RARA [present]",
         "['Arsenic trioxide']",
         "Monotherapy",
         "['PML::RARA inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf",
         "2020-10-20",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.\nIndication: TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.\nCancer type: APL with PML-RARA\nBiomarkers: PML::RARA [present]\nTherapy: Arsenic trioxide\nTherapy approach: Monotherapy\nTherapy strategy: PML::RARA inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf\nPublication date: 2020-10-20",
         "{\"cancer_type\": [\"APL with PML-RARA\"], \"biomarker\": [\"PML\", \"RARA\"]}",
         "{\"cancer_type\": [\"APL WITH PML-RARA\"], \"biomarker\": [\"PML\", \"RARA\"]}"
        ],
        [
         "29",
         "32",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
         "SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
         "Chronic Myelogenous Leukemia",
         "BCR::ABL1 [present]",
         "['Asciminib']",
         "Monotherapy",
         "['BCR-ABL inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
         "2024-10-29",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\nIndication: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
         "{\"cancer_type\": [\"Chronic Myelogenous Leukemia\"], \"biomarker\": [\"BCR\", \"ABL1\"]}",
         "{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "30",
         "33",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.",
         "SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.",
         "Chronic Myelogenous Leukemia",
         "BCR::ABL1 [present], ABL1 p.T315I [present]",
         "['Asciminib']",
         "Monotherapy",
         "['BCR-ABL inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
         "2024-10-29",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.\nIndication: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present], ABL1 p.T315I [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
         "{\"cancer_type\": [\"Chronic Myelogenous Leukemia\"], \"biomarker\": [\"BCR\", \"ABL1\"]}",
         "{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "31",
         "34",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
         "Non-Small Cell Lung Cancer",
         "PD-L1 >= 1% [present]",
         "['Atezolizumab']",
         "Monotherapy",
         "['PD-1/PD-L1 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"PD-L1\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"PD-L1\"]}"
        ],
        [
         "32",
         "35",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
         "Non-Small Cell Lung Cancer",
         "PD-L1 >= 50% [present]",
         "['Atezolizumab']",
         "Monotherapy",
         "['PD-1/PD-L1 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 50% [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"PD-L1\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"PD-L1\"]}"
        ],
        [
         "33",
         "36",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
         "Non-Small Cell Lung Cancer",
         "PD-L1 >= 10% TIIC [present]",
         "['Atezolizumab']",
         "Monotherapy",
         "['PD-1/PD-L1 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 10% TIIC [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"PD-L1\", \"TIIC\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"PD-L1\", \"TIIC\"]}"
        ],
        [
         "34",
         "37",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.",
         "Non-Small Cell Lung Cancer",
         "Wild type ALK [present], Wild type EGFR [present]",
         "['Atezolizumab', 'Bevacizumab', 'Paclitaxel', 'Carboplatin']",
         "Combination therapy",
         "['PD-1/PD-L1 inhibition', 'VEGF inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']",
         "['Immunotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + VEGF inhibition + Taxane-based chemotherapy + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"ALK\", \"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ALK\", \"EGFR\"]}"
        ],
        [
         "35",
         "38",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.",
         "Non-Small Cell Lung Cancer",
         "Wild type ALK [present], Wild type EGFR [present]",
         "['Atezolizumab', 'Paclitaxel', 'Carboplatin']",
         "Combination therapy",
         "['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']",
         "['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Atezolizumab + Paclitaxel + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + Taxane-based chemotherapy + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"ALK\", \"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ALK\", \"EGFR\"]}"
        ],
        [
         "36",
         "39",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.",
         "Non-Small Cell Lung Cancer",
         "EGFR somatic variants [present]",
         "['Atezolizumab']",
         "Monotherapy",
         "['PD-1/PD-L1 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR somatic variants [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"EGFR\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"EGFR\"]}"
        ],
        [
         "37",
         "40",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.",
         "Non-Small Cell Lung Cancer",
         "v::ALK [present]",
         "['Atezolizumab']",
         "Monotherapy",
         "['PD-1/PD-L1 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"ALK\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ALK\"]}"
        ],
        [
         "38",
         "41",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
         "Melanoma",
         "BRAF p.V600E [present]",
         "['Atezolizumab', 'Cobimetinib', 'Vemurafenib']",
         "Combination therapy",
         "['PD-1/PD-L1 inhibition', 'MEK inhibition', 'B-RAF inhibition']",
         "['Immunotherapy', 'Targeted therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Atezolizumab + Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + MEK inhibition + B-RAF inhibition\nTherapy type: Immunotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Melanoma\"], \"biomarker\": [\"BRAF\"]}",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "39",
         "42",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
         "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
         "Melanoma",
         "BRAF p.V600K [present]",
         "['Atezolizumab', 'Cobimetinib', 'Vemurafenib']",
         "Combination therapy",
         "['PD-1/PD-L1 inhibition', 'MEK inhibition', 'B-RAF inhibition']",
         "['Immunotherapy', 'Targeted therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
         "2024-04-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nIndication: TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Atezolizumab + Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + MEK inhibition + B-RAF inhibition\nTherapy type: Immunotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
         "{\"cancer_type\": [\"Melanoma\"], \"biomarker\": [\"BRAF\"]}",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "40",
         "43",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",
         "AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",
         "Gastrointestinal Stromal Tumor",
         "PDGFRA p.D842V [present]",
         "['Avapritinib']",
         "Monotherapy",
         "['KIT inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf",
         "2023-05-22",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\nIndication: AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\nCancer type: Gastrointestinal Stromal Tumor\nBiomarkers: PDGFRA p.D842V [present]\nTherapy: Avapritinib\nTherapy approach: Monotherapy\nTherapy strategy: KIT inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf\nPublication date: 2023-05-22",
         "{\"cancer_type\": [\"Gastrointestinal Stromal Tumor\"], \"biomarker\": [\"PDGFRA\"]}",
         "{\"cancer_type\": [\"GASTROINTESTINAL STROMAL TUMOR\"], \"biomarker\": [\"PDGFRA\"]}"
        ],
        [
         "41",
         "44",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
         "MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
         "Melanoma",
         "BRAF p.V600E [present]",
         "['Binimetinib', 'Encorafenib']",
         "Combination therapy",
         "['MEK inhibition', 'B-RAF inhibition']",
         "['Targeted therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
         "2023-10-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nIndication: MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
         "{\"cancer_type\": [\"Melanoma\"], \"biomarker\": [\"BRAF\"]}",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "42",
         "45",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
         "MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
         "Melanoma",
         "BRAF p.V600K [present]",
         "['Binimetinib', 'Encorafenib']",
         "Combination therapy",
         "['MEK inhibition', 'B-RAF inhibition']",
         "['Targeted therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
         "2023-10-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nIndication: MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
         "{\"cancer_type\": [\"Melanoma\"], \"biomarker\": [\"BRAF\"]}",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "43",
         "46",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
         "MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
         "Non-Small Cell Lung Cancer",
         "BRAF p.V600E [present]",
         "['Binimetinib', 'Encorafenib']",
         "Combination therapy",
         "['MEK inhibition', 'B-RAF inhibition']",
         "['Targeted therapy', 'Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
         "2023-10-11",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.\nIndication: MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
         "{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"], \"biomarker\": [\"BRAF\"]}",
         "{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "44",
         "47",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
         "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
         "Invasive Breast Carcinoma",
         "ER positive [present], HER2-negative [present], PR positive [present]",
         "['Abemaciclib', 'Letrozole']",
         "Combination therapy",
         "['CDK4/6 inhibition', 'Aromatase inhibition']",
         "['Targeted therapy', 'Hormone therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
         "2023-03-03",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nIndication: Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
         "{\"cancer_type\": [\"Invasive Breast Carcinoma\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}",
         "{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"], \"biomarker\": [\"ER\", \"HER2\", \"PR\"]}"
        ],
        [
         "45",
         "48",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
         "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
         "Acute Lymphoid Leukemia",
         "CD19 + [present]",
         "['Blinatumomab']",
         "Monotherapy",
         "['CD19 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
         "2024-06-14",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.\nIndication: BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD19 + [present]\nTherapy: Blinatumomab\nTherapy approach: Monotherapy\nTherapy strategy: CD19 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\nPublication date: 2024-06-14",
         "{\"cancer_type\": [\"Acute Lymphoid Leukemia\"], \"biomarker\": [\"CD19\"]}",
         "{\"cancer_type\": [\"ACUTE LYMPHOID LEUKEMIA\"], \"biomarker\": [\"CD19\"]}"
        ],
        [
         "46",
         "50",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
         "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
         "Acute Lymphoid Leukemia",
         "CD19 + [present], BCR::ABL1 [not present]",
         "['Blinatumomab']",
         "Monotherapy",
         "['CD19 inhibition']",
         "['Immunotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
         "2024-06-14",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.\nIndication: BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD19 + [present], BCR::ABL1 [not present]\nTherapy: Blinatumomab\nTherapy approach: Monotherapy\nTherapy strategy: CD19 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\nPublication date: 2024-06-14",
         "{\"cancer_type\": [\"Acute Lymphoid Leukemia\"], \"biomarker\": [\"CD19\", \"BCR\", \"ABL1\"]}",
         "{\"cancer_type\": [\"ACUTE LYMPHOID LEUKEMIA\"], \"biomarker\": [\"CD19\", \"BCR\", \"ABL1\"]}"
        ],
        [
         "47",
         "51",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
         "BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
         "Chronic Myelogenous Leukemia",
         "BCR::ABL1 [present]",
         "['Bosutinib']",
         "Monotherapy",
         "['BCR-ABL inhibition']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
         "2023-09-26",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\nIndication: BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Bosutinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\nPublication date: 2023-09-26",
         "{\"cancer_type\": [\"Chronic Myelogenous Leukemia\"], \"biomarker\": [\"BCR\", \"ABL1\"]}",
         "{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "48",
         "54",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",
         "ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",
         "Anaplastic Large Cell Lymphoma",
         "CD30 + [present]",
         "['Brentuximab Vedotin', 'Cyclophosphamide', 'Doxorubicin', 'Prednisone']",
         "Combination therapy",
         "['target CD30 antigens', 'Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid']",
         "['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
         "2023-06-14",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.\nIndication: ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.\nCancer type: Anaplastic Large Cell Lymphoma\nBiomarkers: CD30 + [present]\nTherapy: Brentuximab Vedotin + Cyclophosphamide + Doxorubicin + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: target CD30 antigens + Alkylating chemotherapy + Topoisomerase inhibition + Corticosteroid\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf\nPublication date: 2023-06-14",
         "{\"cancer_type\": [\"Anaplastic Large Cell Lymphoma\"], \"biomarker\": [\"CD30\"]}",
         "{\"cancer_type\": [\"ANAPLASTIC LARGE CELL LYMPHOMA\"], \"biomarker\": [\"CD30\"]}"
        ],
        [
         "49",
         "55",
         "Regulatory approval",
         "fda",
         "The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
         "ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
         "Anaplastic Large Cell Lymphoma",
         "CD30 + [present]",
         "['Brentuximab Vedotin']",
         "Monotherapy",
         "['target CD30 antigens']",
         "['Targeted therapy']",
         "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
         "2023-06-14",
         "Approval status: Regulatory approval (fda)\nDescription: The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.\nIndication: ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.\nCancer type: Anaplastic Large Cell Lymphoma\nBiomarkers: CD30 + [present]\nTherapy: Brentuximab Vedotin\nTherapy approach: Monotherapy\nTherapy strategy: target CD30 antigens\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf\nPublication date: 2023-06-14",
         "{\"cancer_type\": [\"Anaplastic Large Cell Lymphoma\"], \"biomarker\": [\"CD30\"]}",
         "{\"cancer_type\": [\"ANAPLASTIC LARGE CELL LYMPHOMA\"], \"biomarker\": [\"CD30\"]}"
        ]
       ],
       "shape": {
        "columns": 16,
        "rows": 584
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>approval_status</th>\n",
       "      <th>approval_org</th>\n",
       "      <th>description</th>\n",
       "      <th>indication</th>\n",
       "      <th>cancer_type</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy_drug</th>\n",
       "      <th>therapy_approach</th>\n",
       "      <th>therapy_strategy</th>\n",
       "      <th>therapy_type</th>\n",
       "      <th>approval_url</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>context</th>\n",
       "      <th>entities_dict</th>\n",
       "      <th>standardized_entities_dict</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Invasive Breast Carcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>HER2-negative [present], PR positive [present]</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Invasive Breast Carcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]...</td>\n",
       "      <td>['Abemaciclib', 'Tamoxifen']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CDK4/6 inhibition', 'Estrogen receptor inhib...</td>\n",
       "      <td>['Targeted therapy', 'Hormone therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Invasive Breast Carcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>ER positive [present], HER2-negative [present]</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['Aromatase inhibition', 'CDK4/6 inhibition']</td>\n",
       "      <td>['Hormone therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Invasive Breast Carcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>Verzenio is a kinase inhibitor indicated in co...</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>HER2-negative [present], PR positive [present]</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['Aromatase inhibition', 'CDK4/6 inhibition']</td>\n",
       "      <td>['Hormone therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2023-03-03</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Invasive Breast Carcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>579</th>\n",
       "      <td>624</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>OPDIVO is a programmed death receptor-1 (PD-1)...</td>\n",
       "      <td>Colorectal Adenocarcinoma</td>\n",
       "      <td>MSI-H [present]</td>\n",
       "      <td>['Ipilimumab', 'Nivolumab']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']</td>\n",
       "      <td>['Immunotherapy', 'Immunotherapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2025-04-11</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Colorectal Adenocarcinoma\"],...</td>\n",
       "      <td>{\"cancer_type\": [\"COLORECTAL ADENOCARCINOMA\"],...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>580</th>\n",
       "      <td>625</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>IBTROZI is a kinase inhibitor indicated for th...</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>v::ROS1 [present]</td>\n",
       "      <td>['Taletrectinib']</td>\n",
       "      <td>Monotherapy</td>\n",
       "      <td>['NTRK inhibition', 'ROS1 inhibition']</td>\n",
       "      <td>['Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2025-06-11</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Non-Small Cell Lung Cancer\"]...</td>\n",
       "      <td>{\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"]...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>581</th>\n",
       "      <td>626</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>EMRELIS is a c-Met-directed antibody and micro...</td>\n",
       "      <td>Lung Non-Squamous Non-Small Cell Carcinoma</td>\n",
       "      <td>c-Met &gt;= 50% [present]</td>\n",
       "      <td>['Telisotuzumab Vedotin']</td>\n",
       "      <td>Monotherapy</td>\n",
       "      <td>['MET inhibition']</td>\n",
       "      <td>['Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2025-05-14</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Lung Non-Squamous Non-Small ...</td>\n",
       "      <td>{\"cancer_type\": [\"LUNG NON-SQUAMOUS NON-SMALL ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>582</th>\n",
       "      <td>627</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>AVMAPKI FAKZYNJA CO-PACK, a combination of avu...</td>\n",
       "      <td>Low-Grade Serous Ovarian Cancer</td>\n",
       "      <td>KRAS p.G12C [present]</td>\n",
       "      <td>['Avutometinib', 'Defactinib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['MEK inhibition', 'RAF inhibition', 'FAK inhi...</td>\n",
       "      <td>['Targeted therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2025-05-08</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Low-Grade Serous Ovarian Can...</td>\n",
       "      <td>{\"cancer_type\": [\"LOW-GRADE SEROUS OVARIAN CAN...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>583</th>\n",
       "      <td>628</td>\n",
       "      <td>Regulatory approval</td>\n",
       "      <td>fda</td>\n",
       "      <td>The U.S. Food and Drug Administration (FDA) gr...</td>\n",
       "      <td>AVMAPKI FAKZYNJA CO-PACK, a combination of avu...</td>\n",
       "      <td>Low-Grade Serous Ovarian Cancer</td>\n",
       "      <td>KRAS p.G12V [present]</td>\n",
       "      <td>['Avutometinib', 'Defactinib']</td>\n",
       "      <td>Combination therapy</td>\n",
       "      <td>['MEK inhibition', 'RAF inhibition', 'FAK inhi...</td>\n",
       "      <td>['Targeted therapy', 'Targeted therapy']</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>2025-05-08</td>\n",
       "      <td>Approval status: Regulatory approval (fda)\\nDe...</td>\n",
       "      <td>{\"cancer_type\": [\"Low-Grade Serous Ovarian Can...</td>\n",
       "      <td>{\"cancer_type\": [\"LOW-GRADE SEROUS OVARIAN CAN...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>584 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     statement_id      approval_status approval_org  \\\n",
       "0               0  Regulatory approval          fda   \n",
       "1               1  Regulatory approval          fda   \n",
       "2               2  Regulatory approval          fda   \n",
       "3               3  Regulatory approval          fda   \n",
       "4               4  Regulatory approval          fda   \n",
       "..            ...                  ...          ...   \n",
       "579           624  Regulatory approval          fda   \n",
       "580           625  Regulatory approval          fda   \n",
       "581           626  Regulatory approval          fda   \n",
       "582           627  Regulatory approval          fda   \n",
       "583           628  Regulatory approval          fda   \n",
       "\n",
       "                                           description  \\\n",
       "0    The U.S. Food and Drug Administration (FDA) gr...   \n",
       "1    The U.S. Food and Drug Administration (FDA) gr...   \n",
       "2    The U.S. Food and Drug Administration (FDA) gr...   \n",
       "3    The U.S. Food and Drug Administration (FDA) gr...   \n",
       "4    The U.S. Food and Drug Administration (FDA) gr...   \n",
       "..                                                 ...   \n",
       "579  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "580  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "581  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "582  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "583  The U.S. Food and Drug Administration (FDA) gr...   \n",
       "\n",
       "                                            indication  \\\n",
       "0    Verzenio is a kinase inhibitor indicated in co...   \n",
       "1    Verzenio is a kinase inhibitor indicated in co...   \n",
       "2    Verzenio is a kinase inhibitor indicated in co...   \n",
       "3    Verzenio is a kinase inhibitor indicated in co...   \n",
       "4    Verzenio is a kinase inhibitor indicated in co...   \n",
       "..                                                 ...   \n",
       "579  OPDIVO is a programmed death receptor-1 (PD-1)...   \n",
       "580  IBTROZI is a kinase inhibitor indicated for th...   \n",
       "581  EMRELIS is a c-Met-directed antibody and micro...   \n",
       "582  AVMAPKI FAKZYNJA CO-PACK, a combination of avu...   \n",
       "583  AVMAPKI FAKZYNJA CO-PACK, a combination of avu...   \n",
       "\n",
       "                                    cancer_type  \\\n",
       "0                     Invasive Breast Carcinoma   \n",
       "1                     Invasive Breast Carcinoma   \n",
       "2                     Invasive Breast Carcinoma   \n",
       "3                     Invasive Breast Carcinoma   \n",
       "4                     Invasive Breast Carcinoma   \n",
       "..                                          ...   \n",
       "579                   Colorectal Adenocarcinoma   \n",
       "580                  Non-Small Cell Lung Cancer   \n",
       "581  Lung Non-Squamous Non-Small Cell Carcinoma   \n",
       "582             Low-Grade Serous Ovarian Cancer   \n",
       "583             Low-Grade Serous Ovarian Cancer   \n",
       "\n",
       "                                             biomarker  \\\n",
       "0       ER positive [present], HER2-negative [present]   \n",
       "1       HER2-negative [present], PR positive [present]   \n",
       "2    ER positive [present], HER2-negative [present]...   \n",
       "3       ER positive [present], HER2-negative [present]   \n",
       "4       HER2-negative [present], PR positive [present]   \n",
       "..                                                 ...   \n",
       "579                                    MSI-H [present]   \n",
       "580                                  v::ROS1 [present]   \n",
       "581                             c-Met >= 50% [present]   \n",
       "582                              KRAS p.G12C [present]   \n",
       "583                              KRAS p.G12V [present]   \n",
       "\n",
       "                       therapy_drug     therapy_approach  \\\n",
       "0      ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "1      ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "2      ['Abemaciclib', 'Tamoxifen']  Combination therapy   \n",
       "3    ['Anastrozole', 'Abemaciclib']  Combination therapy   \n",
       "4    ['Anastrozole', 'Abemaciclib']  Combination therapy   \n",
       "..                              ...                  ...   \n",
       "579     ['Ipilimumab', 'Nivolumab']  Combination therapy   \n",
       "580               ['Taletrectinib']          Monotherapy   \n",
       "581       ['Telisotuzumab Vedotin']          Monotherapy   \n",
       "582  ['Avutometinib', 'Defactinib']  Combination therapy   \n",
       "583  ['Avutometinib', 'Defactinib']  Combination therapy   \n",
       "\n",
       "                                      therapy_strategy  \\\n",
       "0    ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "1    ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "2    ['CDK4/6 inhibition', 'Estrogen receptor inhib...   \n",
       "3        ['Aromatase inhibition', 'CDK4/6 inhibition']   \n",
       "4        ['Aromatase inhibition', 'CDK4/6 inhibition']   \n",
       "..                                                 ...   \n",
       "579     ['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']   \n",
       "580             ['NTRK inhibition', 'ROS1 inhibition']   \n",
       "581                                 ['MET inhibition']   \n",
       "582  ['MEK inhibition', 'RAF inhibition', 'FAK inhi...   \n",
       "583  ['MEK inhibition', 'RAF inhibition', 'FAK inhi...   \n",
       "\n",
       "                                 therapy_type  \\\n",
       "0     ['Targeted therapy', 'Hormone therapy']   \n",
       "1     ['Targeted therapy', 'Hormone therapy']   \n",
       "2     ['Targeted therapy', 'Hormone therapy']   \n",
       "3     ['Hormone therapy', 'Targeted therapy']   \n",
       "4     ['Hormone therapy', 'Targeted therapy']   \n",
       "..                                        ...   \n",
       "579        ['Immunotherapy', 'Immunotherapy']   \n",
       "580                      ['Targeted therapy']   \n",
       "581                      ['Targeted therapy']   \n",
       "582  ['Targeted therapy', 'Targeted therapy']   \n",
       "583  ['Targeted therapy', 'Targeted therapy']   \n",
       "\n",
       "                                          approval_url publication_date  \\\n",
       "0    https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "1    https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "2    https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "3    https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "4    https://www.accessdata.fda.gov/drugsatfda_docs...       2023-03-03   \n",
       "..                                                 ...              ...   \n",
       "579  https://www.accessdata.fda.gov/drugsatfda_docs...       2025-04-11   \n",
       "580  https://www.accessdata.fda.gov/drugsatfda_docs...       2025-06-11   \n",
       "581  https://www.accessdata.fda.gov/drugsatfda_docs...       2025-05-14   \n",
       "582  https://www.accessdata.fda.gov/drugsatfda_docs...       2025-05-08   \n",
       "583  https://www.accessdata.fda.gov/drugsatfda_docs...       2025-05-08   \n",
       "\n",
       "                                               context  \\\n",
       "0    Approval status: Regulatory approval (fda)\\nDe...   \n",
       "1    Approval status: Regulatory approval (fda)\\nDe...   \n",
       "2    Approval status: Regulatory approval (fda)\\nDe...   \n",
       "3    Approval status: Regulatory approval (fda)\\nDe...   \n",
       "4    Approval status: Regulatory approval (fda)\\nDe...   \n",
       "..                                                 ...   \n",
       "579  Approval status: Regulatory approval (fda)\\nDe...   \n",
       "580  Approval status: Regulatory approval (fda)\\nDe...   \n",
       "581  Approval status: Regulatory approval (fda)\\nDe...   \n",
       "582  Approval status: Regulatory approval (fda)\\nDe...   \n",
       "583  Approval status: Regulatory approval (fda)\\nDe...   \n",
       "\n",
       "                                         entities_dict  \\\n",
       "0    {\"cancer_type\": [\"Invasive Breast Carcinoma\"],...   \n",
       "1    {\"cancer_type\": [\"Invasive Breast Carcinoma\"],...   \n",
       "2    {\"cancer_type\": [\"Invasive Breast Carcinoma\"],...   \n",
       "3    {\"cancer_type\": [\"Invasive Breast Carcinoma\"],...   \n",
       "4    {\"cancer_type\": [\"Invasive Breast Carcinoma\"],...   \n",
       "..                                                 ...   \n",
       "579  {\"cancer_type\": [\"Colorectal Adenocarcinoma\"],...   \n",
       "580  {\"cancer_type\": [\"Non-Small Cell Lung Cancer\"]...   \n",
       "581  {\"cancer_type\": [\"Lung Non-Squamous Non-Small ...   \n",
       "582  {\"cancer_type\": [\"Low-Grade Serous Ovarian Can...   \n",
       "583  {\"cancer_type\": [\"Low-Grade Serous Ovarian Can...   \n",
       "\n",
       "                            standardized_entities_dict  \n",
       "0    {\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...  \n",
       "1    {\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...  \n",
       "2    {\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...  \n",
       "3    {\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...  \n",
       "4    {\"cancer_type\": [\"INVASIVE BREAST CARCINOMA\"],...  \n",
       "..                                                 ...  \n",
       "579  {\"cancer_type\": [\"COLORECTAL ADENOCARCINOMA\"],...  \n",
       "580  {\"cancer_type\": [\"NON-SMALL CELL LUNG CANCER\"]...  \n",
       "581  {\"cancer_type\": [\"LUNG NON-SQUAMOUS NON-SMALL ...  \n",
       "582  {\"cancer_type\": [\"LOW-GRADE SEROUS OVARIAN CAN...  \n",
       "583  {\"cancer_type\": [\"LOW-GRADE SEROUS OVARIAN CAN...  \n",
       "\n",
       "[584 rows x 16 columns]"
      ]
     },
     "execution_count": 416,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "moalmanac_new_draft"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 417,
   "id": "23ae7fef",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_new_draft.to_csv(f\"{root_dir}/data/latest_db/moalmanac-draft.dereferenced.unique.context_db.standardized_entities.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c1063971",
   "metadata": {},
   "source": [
    "#### BioBERT NER extraction of entities from synthetic user queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "e1e61eb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "synthetic_query=old_moalmanac_db['prompt'].values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "3a2fdec6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "[{'type': 'Cancer', 'text': 'chronic myelogenous leukemia'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BCR'}, {'type': 'Gene_or_gene_product', 'text': 'ABL1'}]\n",
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n",
      "10\n",
      "[{'type': 'Cancer', 'text': 'cholangiocarcinoma'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'FGFR2'}]\n",
      "{'cancer_type': ['CHOLANGIOCARCINOMA'], 'biomarker': ['FGFR2']}\n",
      "20\n",
      "[{'type': 'Cancer', 'text': 'myelodysplastic'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'PDGFRA'}]\n",
      "{'cancer_type': ['MYELODYSPLASTIC'], 'biomarker': ['PDGFRA']}\n",
      "30\n",
      "[{'type': 'Cancer', 'text': 'melanoma'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRAF'}]\n",
      "{'cancer_type': ['MELANOMA'], 'biomarker': ['BRAF']}\n",
      "40\n",
      "[{'type': 'Cancer', 'text': 'colorectal cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRAF'}]\n",
      "{'cancer_type': ['COLORECTAL CANCER'], 'biomarker': ['BRAF']}\n",
      "50\n",
      "[{'type': 'Cancer', 'text': 'peritoneal cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA1'}]\n",
      "{'cancer_type': ['PERITONEAL CANCER'], 'biomarker': ['BRCA1']}\n",
      "60\n",
      "[{'type': 'Cancer', 'text': 'peritoneal cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA2'}]\n",
      "{'cancer_type': ['PERITONEAL CANCER'], 'biomarker': ['BRCA2']}\n",
      "70\n",
      "[{'type': 'Cancer', 'text': 'prostate cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'CHEK1'}, {'type': 'Cancer', 'text': 'prostate cancer'}]\n",
      "{'cancer_type': ['PROSTATE CANCER', 'PROSTATE CANCER'], 'biomarker': ['CHEK1']}\n",
      "80\n",
      "[{'type': 'Cancer', 'text': 'follicular lymphoma'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'EZH2'}]\n",
      "{'cancer_type': ['FOLLICULAR LYMPHOMA'], 'biomarker': ['EZH2']}\n",
      "90\n",
      "[{'type': 'Cancer', 'text': 'acute myeloid leukemia'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'IDH1'}]\n",
      "{'cancer_type': ['ACUTE MYELOID LEUKEMIA'], 'biomarker': ['IDH1']}\n",
      "100\n",
      "[{'type': 'Cancer', 'text': 'gastrointestinal stromal tumor'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'KIT'}]\n",
      "{'cancer_type': ['GASTROINTESTINAL STROMAL TUMOR'], 'biomarker': ['KIT']}\n",
      "110\n",
      "[{'type': 'Cancer', 'text': 'non - small cell lung cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'MET'}]\n",
      "{'cancer_type': ['NON - SMALL CELL LUNG CANCER'], 'biomarker': ['MET']}\n",
      "120\n",
      "[{'type': 'Cancer', 'text': 'medullary thyroid cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'RET'}]\n",
      "{'cancer_type': ['MEDULLARY THYROID CANCER'], 'biomarker': ['RET']}\n",
      "130\n",
      "[{'type': 'Cancer', 'text': 'breast cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA1'}, {'type': 'Gene_or_gene_product', 'text': 'her2'}]\n",
      "{'cancer_type': ['BREAST CANCER'], 'biomarker': ['BRCA1', 'HER2']}\n",
      "140\n",
      "[{'type': 'Cancer', 'text': 'epithelial ovarian cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA2'}]\n",
      "{'cancer_type': ['EPITHELIAL OVARIAN CANCER'], 'biomarker': ['BRCA2']}\n",
      "150\n",
      "[{'type': 'Cancer', 'text': 'gastic adenocarcinoma'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'ERBB2'}]\n",
      "{'cancer_type': ['GASTIC ADENOCARCINOMA'], 'biomarker': ['ERBB2']}\n",
      "160\n",
      "[{'type': 'Cancer', 'text': 'solid tumor'}, {'type': 'Organism', 'text': 'patient'}]\n",
      "{'cancer_type': ['SOLID TUMOR']}\n",
      "170\n",
      "[{'type': 'Cancer', 'text': 'solid tumor'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'RET'}]\n",
      "{'cancer_type': ['SOLID TUMOR'], 'biomarker': ['RET']}\n",
      "180\n",
      "[{'type': 'Cancer', 'text': 'prostate cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA1'}]\n",
      "{'cancer_type': ['PROSTATE CANCER'], 'biomarker': ['BRCA1']}\n",
      "190\n",
      "[{'type': 'Cancer', 'text': 'prostate cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA1'}]\n",
      "{'cancer_type': ['PROSTATE CANCER'], 'biomarker': ['BRCA1']}\n",
      "200\n",
      "[{'type': 'Cancer', 'text': 'prostate cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BRCA1'}]\n",
      "{'cancer_type': ['PROSTATE CANCER'], 'biomarker': ['BRCA1']}\n",
      "210\n",
      "[{'type': 'Cancer', 'text': 'breast cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'AKT1'}]\n",
      "{'cancer_type': ['BREAST CANCER'], 'biomarker': ['AKT1']}\n",
      "220\n",
      "[{'type': 'Cancer', 'text': 'non - small cell lung cancer'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'EGFR'}]\n",
      "{'cancer_type': ['NON - SMALL CELL LUNG CANCER'], 'biomarker': ['EGFR']}\n",
      "230\n",
      "[{'type': 'Cancer', 'text': 'acute lymphoblastic leukemia'}, {'type': 'Organism', 'text': 'patient'}, {'type': 'Gene_or_gene_product', 'text': 'BCR'}, {'type': 'Gene_or_gene_product', 'text': 'ABL1'}]\n",
      "{'cancer_type': ['ACUTE LYMPHOBLASTIC LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n"
     ]
    }
   ],
   "source": [
    "#extract BioBERT NER from synthetic user queries and standardize entities\n",
    "def query_biobert_ner(query, model, tokenizer):\n",
    "    entities = ner_predict_entities(query, model, tokenizer)\n",
    "    entities_dict = {}\n",
    "    \n",
    "    for e in entities:\n",
    "        if e['type'] == 'Cancer':\n",
    "            entities_dict.setdefault('cancer_type', []).append(e['text'].upper())\n",
    "        if e['type'] == 'Gene_or_gene_product':\n",
    "            entities_dict.setdefault('biomarker', []).append(e['text'].upper())\n",
    "    return entities, entities_dict\n",
    "    \n",
    "#run for all synthetic queries    \n",
    "biobert_entities_list = []\n",
    "standardized_entities_dict_list = []\n",
    "for i, query in enumerate(synthetic_query):\n",
    "    biobert_entities, standardized_entities_dict = query_biobert_ner(query, model, tokenizer)\n",
    "    biobert_entities_list.append(biobert_entities)\n",
    "    standardized_entities_dict_list.append(standardized_entities_dict)    \n",
    "    \n",
    "    if i % 10 == 0:\n",
    "        print(i)\n",
    "        print(biobert_entities)\n",
    "        print(standardized_entities_dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "9a851ad8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# synthetic_query_ner.to_csv(f\"{root_dir}/data/synthetic_query_ner_entities.csv\", index=False)\n",
    "with open(\"entities/synthetic_query_ner_entities.json\", \"w\") as f:\n",
    "    json.dump(standardized_entities_dict_list, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "ae4a5bcd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "234"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "with open(\"entities/synthetic_query_ner_entities.json\", \"r\") as f:\n",
    "    standardized_entities_dict_list = json.load(f)\n",
    "len(standardized_entities_dict_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3927c5c9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "synthetic_queries",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "spacy_ner_bionlp13cg_entities",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "spacy_ner_bc5cdr_entities",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "BioNLP13CG_biobert_ner_entities",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "extracted_entities_dict",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "60d72104-428e-4d35-acb3-2669eb084e1b",
       "rows": [
        [
         "0",
         "If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic, accelerated, or blast phase, what would be the suggested lines of treatment?",
         "(chronic myelogenous leukemia patient, BCR, ABL1, lines)",
         "(chronic myelogenous leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"chronic myelogenous leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BCR\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ABL1\"}]",
         "{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "1",
         "If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, what would be the suggested lines of treatment?",
         "(chronic myelogenous leukemia patient, BCR, ABL1, lines)",
         "(chronic myelogenous leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"chronic myelogenous leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BCR\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ABL1\"}]",
         "{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "2",
         "If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, what would be the suggested lines of treatment?",
         "(acute lymphoblastic leukemia patient, BCR, ABL1, lines)",
         "(acute lymphoblastic leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"acute lymphoblastic leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BCR\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ABL1\"}]",
         "{\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "3",
         "If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, what would be the suggested lines of treatment?",
         "(acute lymphoblastic leukemia patient, BCR, ABL1, lines)",
         "(acute lymphoblastic leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"acute lymphoblastic leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BCR\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ABL1\"}]",
         "{\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "4",
         "If a chronic myeloid leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, what would be the suggested lines of treatment?",
         "(chronic myeloid leukemia patient, BCR, ABL1, lines)",
         "(chronic myeloid leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"chronic myeloid leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BCR\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ABL1\"}]",
         "{\"cancer_type\": [\"CHRONIC MYELOID LEUKEMIA\"], \"biomarker\": [\"BCR\", \"ABL1\"]}"
        ],
        [
         "5",
         "If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, what would be the suggested lines of treatment?",
         "(non-small cell lung cancer patient, ALK, lines)",
         "(non-small cell lung cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"non - small cell lung cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ALK\"}]",
         "{\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ALK\"]}"
        ],
        [
         "6",
         "If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, what would be the suggested lines of treatment?",
         "(cholangiocarcinoma patient, FGFR2, lines)",
         "(cholangiocarcinoma,)",
         "[{\"type\": \"Cancer\", \"text\": \"cholangiocarcinoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"FGFR2\"}]",
         "{\"cancer_type\": [\"CHOLANGIOCARCINOMA\"], \"biomarker\": [\"FGFR2\"]}"
        ],
        [
         "7",
         "If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, what would be the suggested lines of treatment?",
         "(cholangiocarcinoma patient, FGFR2, lines)",
         "(cholangiocarcinoma,)",
         "[{\"type\": \"Cancer\", \"text\": \"cholangiocarcinoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"FGFR2\"}]",
         "{\"cancer_type\": [\"CHOLANGIOCARCINOMA\"], \"biomarker\": [\"FGFR2\"]}"
        ],
        [
         "8",
         "If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., what would be the suggested lines of treatment?",
         "(urothelial carcinoma patient, FGFR3, lines)",
         "(urothelial carcinoma,)",
         "[{\"type\": \"Cancer\", \"text\": \"urothelial carcinoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"FGFR3\"}]",
         "{\"cancer_type\": [\"UROTHELIAL CARCINOMA\"], \"biomarker\": [\"FGFR3\"]}"
        ],
        [
         "9",
         "If a any solid tumor patient has a rearrangement in gene NTRK1, what would be the suggested lines of treatment?",
         "(solid tumor patient, NTRK1, lines)",
         "(tumor,)",
         "[{\"type\": \"Cancer\", \"text\": \"solid tumor\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"NTRK1\"}]",
         "{\"cancer_type\": [\"SOLID TUMOR\"], \"biomarker\": [\"NTRK1\"]}"
        ],
        [
         "10",
         "If a any solid tumor patient has a rearrangement in gene NTRK2, what would be the suggested lines of treatment?",
         "(solid tumor patient, NTRK2, lines)",
         "(tumor,)",
         "[{\"type\": \"Cancer\", \"text\": \"solid tumor\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"NTRK2\"}]",
         "{\"cancer_type\": [\"SOLID TUMOR\"], \"biomarker\": [\"NTRK2\"]}"
        ],
        [
         "11",
         "If a any solid tumor patient has a rearrangement in gene NTRK3, what would be the suggested lines of treatment?",
         "(solid tumor patient, NTRK3, lines)",
         "(tumor,)",
         "[{\"type\": \"Cancer\", \"text\": \"solid tumor\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"NTRK3\"}]",
         "{\"cancer_type\": [\"SOLID TUMOR\"], \"biomarker\": [\"NTRK3\"]}"
        ],
        [
         "12",
         "If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, what would be the suggested lines of treatment?",
         "(patient, PDGFRA, lines)",
         "(myelodysplastic syndromes,)",
         "[{\"type\": \"Cancer\", \"text\": \"myelodysplastic\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"PDGFRA\"}]",
         "{\"cancer_type\": [\"MYELODYSPLASTIC\"], \"biomarker\": [\"PDGFRA\"]}"
        ],
        [
         "13",
         "If a chronic eosinophilic leukemia patient has a rearrangement in gene FIP1L1 and PDGFRA, what would be the suggested lines of treatment?",
         "(eosinophilic leukemia patient, FIP1L1, PDGFRA, lines)",
         "(chronic eosinophilic leukemia,)",
         "[{\"type\": \"Cancer\", \"text\": \"chronic eosinophilic leukemia\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"FIP1L1\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"PDGFRA\"}]",
         "{\"cancer_type\": [\"CHRONIC EOSINOPHILIC LEUKEMIA\"], \"biomarker\": [\"FIP1L1\", \"PDGFRA\"]}"
        ],
        [
         "14",
         "If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, what would be the suggested lines of treatment?",
         "(patient, PDGFRB, lines)",
         "(myelodysplastic syndromes,)",
         "[{\"type\": \"Cancer\", \"text\": \"myelodysplastic\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"PDGFRB\"}]",
         "{\"cancer_type\": [\"MYELODYSPLASTIC\"], \"biomarker\": [\"PDGFRB\"]}"
        ],
        [
         "15",
         "If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, what would be the suggested lines of treatment?",
         "(non-small cell lung cancer patient, RET, lines)",
         "(non-small cell lung cancer, RET)",
         "[{\"type\": \"Cancer\", \"text\": \"non - small cell lung cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"RET\"}]",
         "{\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER\"], \"biomarker\": [\"RET\"]}"
        ],
        [
         "16",
         "If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, what would be the suggested lines of treatment?",
         "(thyroid cancer patient, RET, lines)",
         "(thyroid cancer, RET)",
         "[{\"type\": \"Cancer\", \"text\": \"thyroid cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"RET\"}]",
         "{\"cancer_type\": [\"THYROID CANCER\"], \"biomarker\": [\"RET\"]}"
        ],
        [
         "17",
         "If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, what would be the suggested lines of treatment?",
         "(non-small cell lung cancer patient, ROS1, lines)",
         "(non-small cell lung cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"non - small cell lung cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ROS1\"}]",
         "{\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER\"], \"biomarker\": [\"ROS1\"]}"
        ],
        [
         "18",
         "If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, what would be the suggested lines of treatment?",
         "(prostate cancer patient, ATM, prostate cancer, lines)",
         "(prostate cancer, ATM, prostate cancer)",
         "[{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"ATM\"}, {\"type\": \"Cancer\", \"text\": \"prostate cancer\"}]",
         "{\"cancer_type\": [\"PROSTATE CANCER\", \"PROSTATE CANCER\"], \"biomarker\": [\"ATM\"]}"
        ],
        [
         "19",
         "If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, what would be the suggested lines of treatment?",
         "(prostate cancer patient, BARD1, prostate cancer, lines)",
         "(prostate cancer, prostate cancer)",
         "[{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BARD1\"}, {\"type\": \"Cancer\", \"text\": \"prostate cancer\"}]",
         "{\"cancer_type\": [\"PROSTATE CANCER\", \"PROSTATE CANCER\"], \"biomarker\": [\"BARD1\"]}"
        ],
        [
         "20",
         "If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, what would be the suggested lines of treatment?",
         "(melanoma patient, BRAF, c.1799T, lines)",
         "(melanoma,)",
         "[{\"type\": \"Cancer\", \"text\": \"melanoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "21",
         "If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, what would be the suggested lines of treatment?",
         "(melanoma patient, BRAF, c.1798_1799GT, lines)",
         "(melanoma, AA, V600K)",
         "[{\"type\": \"Cancer\", \"text\": \"melanoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "22",
         "If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), what would be the suggested lines of treatment?",
         "(melanoma patient, BRAF, c.1799T, lines)",
         "(melanoma,)",
         "[{\"type\": \"Cancer\", \"text\": \"melanoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "23",
         "If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), what would be the suggested lines of treatment?",
         "(melanoma patient, BRAF, c.1798_1799GT, lines)",
         "(melanoma, AA, V600K)",
         "[{\"type\": \"Cancer\", \"text\": \"melanoma\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"MELANOMA\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "24",
         "If a non-small cell lung cancer patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is metastatic, what would be the suggested lines of treatment?",
         "(non-small cell lung cancer patient, BRAF, c.1799T, lines)",
         "(non-small cell lung cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"non - small cell lung cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "25",
         "If a colorectal cancer patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is metastatic, after prior therapy, what would be the suggested lines of treatment?",
         "(colorectal cancer patient, BRAF, c.1799T, lines)",
         "(colorectal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"colorectal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRAF\"}]",
         "{\"cancer_type\": [\"COLORECTAL CANCER\"], \"biomarker\": [\"BRAF\"]}"
        ],
        [
         "26",
         "If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, what would be the suggested lines of treatment?",
         "(epithelial ovarian cancer patient, BRCA1, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"epithelial ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"EPITHELIAL OVARIAN CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "27",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA1, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA1, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "28",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA1, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "29",
         "If a ovarian cancer patient has a somatic variant in gene BRCA1, and is previously treated with 2 or more chemotherapies, what would be the suggested lines of treatment?",
         "(ovarian cancer patient, BRCA1, chemotherapies, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"OVARIAN CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "30",
         "If a fallopian tube patient has a somatic variant in gene BRCA1, what would be the suggested lines of treatment?",
         "(fallopian tube, patient, BRCA1, lines)",
         "()",
         "[{\"type\": \"Organ\", \"text\": \"fallopian\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "31",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is previously treated with 2 or more chemotherapies, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA1, chemotherapies, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "32",
         "If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(ovarian cancer patient, BRCA1, lines, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"OVARIAN CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "33",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA1, lines, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "34",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA1, lines, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "35",
         "If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, what would be the suggested lines of treatment?",
         "(prostate cancer patient, BRCA1, prostate cancer, lines)",
         "(prostate cancer, prostate cancer)",
         "[{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}, {\"type\": \"Cancer\", \"text\": \"prostate cancer\"}]",
         "{\"cancer_type\": [\"PROSTATE CANCER\", \"PROSTATE CANCER\"], \"biomarker\": [\"BRCA1\"]}"
        ],
        [
         "36",
         "If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, what would be the suggested lines of treatment?",
         "(epithelial ovarian cancer patient, BRCA1, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"epithelial ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"hrd\"}]",
         "{\"cancer_type\": [\"EPITHELIAL OVARIAN CANCER\"], \"biomarker\": [\"BRCA1\", \"HRD\"]}"
        ],
        [
         "37",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA1, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"hrd\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA1\", \"HRD\"]}"
        ],
        [
         "38",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA1, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA1\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"hrd\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA1\", \"HRD\"]}"
        ],
        [
         "39",
         "If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(ovarian cancer patient, BRCA2, lines, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"OVARIAN CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "40",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA2, lines, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "41",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA2, lines, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "42",
         "If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, what would be the suggested lines of treatment?",
         "(epithelial ovarian cancer patient, BRCA2, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"epithelial ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"EPITHELIAL OVARIAN CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "43",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA2, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA2, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "44",
         "If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, what would be the suggested lines of treatment?",
         "(peritoneal cancer patient, BRCA2, lines)",
         "(peritoneal cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"peritoneal cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"PERITONEAL CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "45",
         "If a ovarian cancer patient has a somatic variant in gene BRCA2, and is previously treated with 2 or more chemotherapies, what would be the suggested lines of treatment?",
         "(ovarian cancer patient, BRCA2, chemotherapies, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"cancer_type\": [\"OVARIAN CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "46",
         "If a fallopian tube patient has a somatic variant in gene BRCA2, and is previously treated with 2 or more chemotherapies, what would be the suggested lines of treatment?",
         "(fallopian tube, patient, BRCA2, chemotherapies, lines)",
         "()",
         "[{\"type\": \"Multi-tissue_structure\", \"text\": \"fallopian tube\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}]",
         "{\"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "47",
         "If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, what would be the suggested lines of treatment?",
         "(prostate cancer patient, BRCA2, prostate cancer, lines)",
         "(prostate cancer, prostate cancer)",
         "[{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}, {\"type\": \"Cancer\", \"text\": \"prostate cancer\"}]",
         "{\"cancer_type\": [\"PROSTATE CANCER\", \"PROSTATE CANCER\"], \"biomarker\": [\"BRCA2\"]}"
        ],
        [
         "48",
         "If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, what would be the suggested lines of treatment?",
         "(epithelial ovarian cancer patient, BRCA2, lines)",
         "(ovarian cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"epithelial ovarian cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"hrd\"}]",
         "{\"cancer_type\": [\"EPITHELIAL OVARIAN CANCER\"], \"biomarker\": [\"BRCA2\", \"HRD\"]}"
        ],
        [
         "49",
         "If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, what would be the suggested lines of treatment?",
         "(fallopian tube cancer patient, BRCA2, lines)",
         "(fallopian tube cancer,)",
         "[{\"type\": \"Cancer\", \"text\": \"fallopian tube cancer\"}, {\"type\": \"Organism\", \"text\": \"patient\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"BRCA2\"}, {\"type\": \"Gene_or_gene_product\", \"text\": \"hrd\"}]",
         "{\"cancer_type\": [\"FALLOPIAN TUBE CANCER\"], \"biomarker\": [\"BRCA2\", \"HRD\"]}"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 183
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>synthetic_queries</th>\n",
       "      <th>spacy_ner_bionlp13cg_entities</th>\n",
       "      <th>spacy_ner_bc5cdr_entities</th>\n",
       "      <th>BioNLP13CG_biobert_ner_entities</th>\n",
       "      <th>extracted_entities_dict</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>If a chronic myelogenous leukemia patient has ...</td>\n",
       "      <td>(chronic myelogenous leukemia patient, BCR, AB...</td>\n",
       "      <td>(chronic myelogenous leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"chronic myelogeno...</td>\n",
       "      <td>{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>If a chronic myelogenous leukemia patient has ...</td>\n",
       "      <td>(chronic myelogenous leukemia patient, BCR, AB...</td>\n",
       "      <td>(chronic myelogenous leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"chronic myelogeno...</td>\n",
       "      <td>{\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>If a acute lymphoblastic leukemia patient has ...</td>\n",
       "      <td>(acute lymphoblastic leukemia patient, BCR, AB...</td>\n",
       "      <td>(acute lymphoblastic leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...</td>\n",
       "      <td>{\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>If a acute lymphoblastic leukemia patient has ...</td>\n",
       "      <td>(acute lymphoblastic leukemia patient, BCR, AB...</td>\n",
       "      <td>(acute lymphoblastic leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...</td>\n",
       "      <td>{\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>If a chronic myeloid leukemia patient has a re...</td>\n",
       "      <td>(chronic myeloid leukemia patient, BCR, ABL1, ...</td>\n",
       "      <td>(chronic myeloid leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"chronic myeloid l...</td>\n",
       "      <td>{\"cancer_type\": [\"CHRONIC MYELOID LEUKEMIA\"], ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>178</th>\n",
       "      <td>If a anaplastic large cell lymphoma (alcl) pat...</td>\n",
       "      <td>(anaplastic large cell lymphoma, patient, ALK,...</td>\n",
       "      <td>(anaplastic, large cell lymphoma, alcl)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"anaplastic large ...</td>\n",
       "      <td>{\"cancer_type\": [\"ANAPLASTIC LARGE CELL LYMPHO...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>179</th>\n",
       "      <td>If a non-small cell lung cancer patient has a ...</td>\n",
       "      <td>(non-small cell lung cancer patient, ROS1, lines)</td>\n",
       "      <td>(non-small cell lung cancer,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"non - small cell ...</td>\n",
       "      <td>{\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>180</th>\n",
       "      <td>If a prostate cancer patient has a somatic var...</td>\n",
       "      <td>(prostate cancer patient, MRE11, lines)</td>\n",
       "      <td>(prostate cancer, castration-resistant)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}...</td>\n",
       "      <td>{\"cancer_type\": [\"PROSTATE CANCER\"], \"biomarke...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>If a acute lymphoblastic leukemia patient has ...</td>\n",
       "      <td>(acute lymphoblastic leukemia patient, ABL1, l...</td>\n",
       "      <td>(acute lymphoblastic leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...</td>\n",
       "      <td>{\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>If a chronic myeloid leukemia patient has a so...</td>\n",
       "      <td>(chronic myeloid leukemia patient, ABL1, lines)</td>\n",
       "      <td>(chronic myeloid leukemia,)</td>\n",
       "      <td>[{\"type\": \"Cancer\", \"text\": \"chronic myeloid l...</td>\n",
       "      <td>{\"cancer_type\": [\"CHRONIC MYELOID LEUKEMIA\"], ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>183 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     synthetic_queries  \\\n",
       "0    If a chronic myelogenous leukemia patient has ...   \n",
       "1    If a chronic myelogenous leukemia patient has ...   \n",
       "2    If a acute lymphoblastic leukemia patient has ...   \n",
       "3    If a acute lymphoblastic leukemia patient has ...   \n",
       "4    If a chronic myeloid leukemia patient has a re...   \n",
       "..                                                 ...   \n",
       "178  If a anaplastic large cell lymphoma (alcl) pat...   \n",
       "179  If a non-small cell lung cancer patient has a ...   \n",
       "180  If a prostate cancer patient has a somatic var...   \n",
       "181  If a acute lymphoblastic leukemia patient has ...   \n",
       "182  If a chronic myeloid leukemia patient has a so...   \n",
       "\n",
       "                         spacy_ner_bionlp13cg_entities  \\\n",
       "0    (chronic myelogenous leukemia patient, BCR, AB...   \n",
       "1    (chronic myelogenous leukemia patient, BCR, AB...   \n",
       "2    (acute lymphoblastic leukemia patient, BCR, AB...   \n",
       "3    (acute lymphoblastic leukemia patient, BCR, AB...   \n",
       "4    (chronic myeloid leukemia patient, BCR, ABL1, ...   \n",
       "..                                                 ...   \n",
       "178  (anaplastic large cell lymphoma, patient, ALK,...   \n",
       "179  (non-small cell lung cancer patient, ROS1, lines)   \n",
       "180            (prostate cancer patient, MRE11, lines)   \n",
       "181  (acute lymphoblastic leukemia patient, ABL1, l...   \n",
       "182    (chronic myeloid leukemia patient, ABL1, lines)   \n",
       "\n",
       "                   spacy_ner_bc5cdr_entities  \\\n",
       "0            (chronic myelogenous leukemia,)   \n",
       "1            (chronic myelogenous leukemia,)   \n",
       "2            (acute lymphoblastic leukemia,)   \n",
       "3            (acute lymphoblastic leukemia,)   \n",
       "4                (chronic myeloid leukemia,)   \n",
       "..                                       ...   \n",
       "178  (anaplastic, large cell lymphoma, alcl)   \n",
       "179            (non-small cell lung cancer,)   \n",
       "180  (prostate cancer, castration-resistant)   \n",
       "181          (acute lymphoblastic leukemia,)   \n",
       "182              (chronic myeloid leukemia,)   \n",
       "\n",
       "                       BioNLP13CG_biobert_ner_entities  \\\n",
       "0    [{\"type\": \"Cancer\", \"text\": \"chronic myelogeno...   \n",
       "1    [{\"type\": \"Cancer\", \"text\": \"chronic myelogeno...   \n",
       "2    [{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...   \n",
       "3    [{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...   \n",
       "4    [{\"type\": \"Cancer\", \"text\": \"chronic myeloid l...   \n",
       "..                                                 ...   \n",
       "178  [{\"type\": \"Cancer\", \"text\": \"anaplastic large ...   \n",
       "179  [{\"type\": \"Cancer\", \"text\": \"non - small cell ...   \n",
       "180  [{\"type\": \"Cancer\", \"text\": \"prostate cancer\"}...   \n",
       "181  [{\"type\": \"Cancer\", \"text\": \"acute lymphoblast...   \n",
       "182  [{\"type\": \"Cancer\", \"text\": \"chronic myeloid l...   \n",
       "\n",
       "                               extracted_entities_dict  \n",
       "0    {\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA...  \n",
       "1    {\"cancer_type\": [\"CHRONIC MYELOGENOUS LEUKEMIA...  \n",
       "2    {\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...  \n",
       "3    {\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...  \n",
       "4    {\"cancer_type\": [\"CHRONIC MYELOID LEUKEMIA\"], ...  \n",
       "..                                                 ...  \n",
       "178  {\"cancer_type\": [\"ANAPLASTIC LARGE CELL LYMPHO...  \n",
       "179  {\"cancer_type\": [\"NON - SMALL CELL LUNG CANCER...  \n",
       "180  {\"cancer_type\": [\"PROSTATE CANCER\"], \"biomarke...  \n",
       "181  {\"cancer_type\": [\"ACUTE LYMPHOBLASTIC LEUKEMIA...  \n",
       "182  {\"cancer_type\": [\"CHRONIC MYELOID LEUKEMIA\"], ...  \n",
       "\n",
       "[183 rows x 5 columns]"
      ]
     },
     "execution_count": 457,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#load all ner results\n",
    "ner_entities=pd.read_csv(os.path.join(root_dir, 'data/synthetic_query_ner_entities_all_methods.csv'))\n",
    "\n",
    "#merge biobert ner entities\n",
    "ner_entities['BioNLP13CG_biobert_ner_entities'] = synthetic_query_ner['biobert_entities']\n",
    "ner_entities['extracted_entities_dict'] = synthetic_query_ner['standardized_entities_dict']\n",
    "ner_entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1e9142e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "ner_entities.to_csv(f\"{root_dir}/data/synthetic_query_ner_entities_all_methods.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f028700f",
   "metadata": {},
   "source": [
    "### Exact and fuzzy matching"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d29dd602",
   "metadata": {},
   "source": [
    "Load synthetic query entities and db entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 475,
   "id": "61710cd3",
   "metadata": {},
   "outputs": [],
   "source": [
    "#load synthetic query entities \n",
    "synthetic_query_ner = pd.read_csv(f\"{root_dir}/data/synthetic_query_ner_entities.csv\")\n",
    "synthetic_query_ner[\"standardized_entities_dict\"] = synthetic_query_ner[\"standardized_entities_dict\"].apply(ast.literal_eval)\n",
    "\n",
    "#and moalmanac entities\n",
    "moalmanac_db = pd.read_csv(f\"{root_dir}/data/latest_db/moalmanac-draft.dereferenced.unique.context_db.standardized_entities.csv\")\n",
    "moalmanac_db['standardized_entities_dict'] = moalmanac_db['standardized_entities_dict'].apply(ast.literal_eval)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 505,
   "id": "c91255b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "from rapidfuzz import fuzz\n",
    "\n",
    "def check_list(input):\n",
    "    if isinstance(input, list):\n",
    "        input = input\n",
    "    else:\n",
    "        input = [input]\n",
    "    return input\n",
    "\n",
    "def match_entities(user_entities, db, fuzzy_thres=70, id_col='statement_id', entities_col='standardized_entities_dict', context_col='context'):\n",
    "    \"\"\"\n",
    "    Calculate score based on matching cancer types and biomarkers between user's query and the database\n",
    "    \n",
    "        Arguments:\n",
    "        user_entities (dict): A dictionary with 'cancer_type' and 'biomarker' entities extracted using biobert\n",
    "        db (DataFrame): A context database with 'cancer_type' and 'biomarker' entities extracted using biobert, context, and id\n",
    "\n",
    "    \"\"\"\n",
    "    \n",
    "    user_cancer = user_entities['cancer_type']\n",
    "    user_biomarker = user_entities['biomarker']\n",
    "    user_cancer = check_list(user_cancer)\n",
    "    user_biomarker = check_list(user_biomarker)\n",
    "    match_score_all=[]\n",
    "    \n",
    "    #iterate over all db entities\n",
    "    for idx, row in db.iterrows():\n",
    "        #entities dict\n",
    "        db_entities = row[entities_col]\n",
    "        \n",
    "        #initialize matching score\n",
    "        score=0\n",
    "        \n",
    "        #append matching count\n",
    "        for db_cancer in db_entities['cancer_type']: \n",
    "            db_cancer = check_list(db_cancer)\n",
    "            if len(set(db_cancer) & set(user_cancer)) > 0:\n",
    "                score += len(set(db_cancer) & set(user_cancer))\n",
    "            elif any(fuzz.ratio(dbc, uc) > fuzzy_thres for uc in user_cancer for dbc in db_cancer):\n",
    "                score += 0.5\n",
    "        \n",
    "        for db_biomarker in db_entities['biomarker']:\n",
    "            db_biomarker = check_list(db_biomarker)\n",
    "            if len(set(db_biomarker) & set(user_biomarker)) > 0:\n",
    "                score += len(set(db_biomarker) & set(user_biomarker))\n",
    "            elif any(fuzz.ratio(dbb, ub) > fuzzy_thres for ub in user_biomarker for dbb in db_biomarker):\n",
    "                score += 0.5\n",
    "\n",
    "        if score > 0:\n",
    "            match_score_all.append((row[id_col], score, row[entities_col], row[context_col]))\n",
    "        \n",
    "    #sort by score descending\n",
    "    match_score_all.sort(key=lambda x: x[1], reverse=True)\n",
    "    return match_score_all"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 508,
   "id": "92e5dd75",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[(32,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\\nIndication: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Asciminib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\\nPublication date: 2024-10-29'),\n",
       " (33,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.\\nIndication: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present], ABL1 p.T315I [present]\\nTherapy: Asciminib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\\nPublication date: 2024-10-29'),\n",
       " (51,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\\nIndication: BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Bosutinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\\nPublication date: 2023-09-26'),\n",
       " (106,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\\nIndication: SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Dasatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\\nPublication date: 2023-02-08'),\n",
       " (180,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nIndication: Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Imatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\\nPublication date: 2024-03-01'),\n",
       " (251,\n",
       "  3,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nIndication: Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Nilotinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\\nPublication date: 2024-02-29'),\n",
       " (50,\n",
       "  2,\n",
       "  {'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'],\n",
       "   'biomarker': ['CD19', 'BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.\\nIndication: BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.\\nCancer type: Acute Lymphoid Leukemia\\nBiomarkers: CD19 + [present], BCR::ABL1 [not present]\\nTherapy: Blinatumomab\\nTherapy approach: Monotherapy\\nTherapy strategy: CD19 inhibition\\nTherapy type: Immunotherapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\\nPublication date: 2024-06-14'),\n",
       " (107,\n",
       "  2,\n",
       "  {'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\\nIndication: SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Dasatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\\nPublication date: 2023-02-08'),\n",
       " (110,\n",
       "  2,\n",
       "  {'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\\nIndication: SPRYCEL is a kinase inhibitor indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\\nCancer type: Acute Lymphoid Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Dasatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\\nPublication date: 2023-02-08'),\n",
       " (181,\n",
       "  2,\n",
       "  {'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nIndication: Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Imatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\\nPublication date: 2024-03-01'),\n",
       " (184,\n",
       "  2,\n",
       "  {'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\\nIndication: Gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\\nCancer type: Acute Lymphoid Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Imatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\\nPublication date: 2024-03-01'),\n",
       " (252,\n",
       "  2,\n",
       "  {'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nIndication: Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Nilotinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\\nPublication date: 2024-02-29'),\n",
       " (426,\n",
       "  2,\n",
       "  {'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).\\nIndication: ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).\\nCancer type: Acute Lymphoid Leukemia\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Cytarabine + Methotrexate + Ponatinib + Prednisone + Vincristine\\nTherapy approach: Combination therapy\\nTherapy strategy: DNA Polymerase inhibition + Antifolate + BCR-ABL inhibition + Corticosteroid + Vinca alkaloid chemotherapy\\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy + Chemotherapy + Chemotherapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\\nPublication date: 2024-03-19'),\n",
       " (427,\n",
       "  2,\n",
       "  {'cancer_type': ['ACUTE LYMPHOID LEUKEMIA'], 'biomarker': ['ABL1', 'BCR']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.\\nIndication: ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with as monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.\\nCancer type: Acute Lymphoid Leukemia\\nBiomarkers: ABL1 p.T315I [present], BCR::ABL1 [present]\\nTherapy: Ponatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\\nPublication date: 2024-03-19'),\n",
       " (428,\n",
       "  2,\n",
       "  {'cancer_type': ['CHRONIC MYELOGENOUS LEUKEMIA'], 'biomarker': ['ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.\\nIndication: ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase). Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.\\nCancer type: Chronic Myelogenous Leukemia\\nBiomarkers: ABL1 p.T315I [present]\\nTherapy: Ponatinib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\\nPublication date: 2024-03-19'),\n",
       " (607,\n",
       "  2,\n",
       "  {'cancer_type': ['CHRONIC MYELOID LEUKEMIA, BCR-ABL1+'],\n",
       "   'biomarker': ['BCR', 'ABL1']},\n",
       "  'Approval status: Regulatory approval (fda)\\nDescription: The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).\\nIndication: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).\\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\\nBiomarkers: BCR::ABL1 [present]\\nTherapy: Asciminib\\nTherapy approach: Monotherapy\\nTherapy strategy: BCR-ABL inhibition\\nTherapy type: Targeted therapy\\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\\nPublication date: 2024-10-29')]"
      ]
     },
     "execution_count": 508,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test_idx_list = split_ranges(synthetic_query_ner.shape[0], 10, 50)\n",
    "test_idx = 0\n",
    "match_score_all=match_entities(synthetic_query_ner['standardized_entities_dict'][test_idx], moalmanac_db)\n",
    "print(synthetic_query_ner['standardized_entities_dict'][test_idx])\n",
    "match_score_all"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2c09d3e4",
   "metadata": {},
   "source": [
    "## Rerank based on semantic similarity using BioBERT embeddings"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "583fc193",
   "metadata": {},
   "source": [
    "Next, we can also try enhancing the semantic search by using embedding models pretrained on biomedical text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "54383092",
   "metadata": {},
   "source": [
    "BioBERT finetuned for sentence semantic search:\n",
    "- pritamdeka/S-PubMedBert-MS-MARCO (https://huggingface.co/pritamdeka/S-PubMedBert-MS-MARCO)\n",
    "- "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "16ef8d23",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-base-cased-v1.1\")\n",
    "model = AutoModel.from_pretrained(\"dmis-lab/biobert-base-cased-v1.1\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "2d5453fe",
   "metadata": {},
   "outputs": [],
   "source": [
    "def embed_text(text):\n",
    "    inputs = tokenizer(text, return_tensors='pt', truncation=True, max_length=128)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs)\n",
    "    # using [CLS] token embedding as sentence representation\n",
    "    return outputs.last_hidden_state[:,0,:].numpy()\n",
    "\n",
    "def find_semantic_matches(moalmanac_list, user_list, threshold=0.7):\n",
    "    \"\"\"\n",
    "    Return semantic matches using BioBERT embeddings.\n",
    "    \"\"\"\n",
    "    matches = []\n",
    "    moalmanac_embeddings = [embed_text(b) for b in moalmanac_list]\n",
    "    user_embeddings = [embed_text(u) for u in user_list]\n",
    "    \n",
    "    for i, b in enumerate(moalmanac_list):\n",
    "        b_vec = moalmanac_embeddings[i]\n",
    "        matched = []\n",
    "        for j, u in enumerate(user_list):\n",
    "            u_vec = user_embeddings[j]\n",
    "            sim = cosine_similarity(b_vec, u_vec)[0][0]\n",
    "            if sim >= threshold:\n",
    "                matched.append(u)\n",
    "        if matched:\n",
    "            matches.append((b, matched))\n",
    "    return matches\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fd31db57",
   "metadata": {},
   "outputs": [],
   "source": [
    "# find_semantic_matches(moalmanac_new_draft['standardized_entities_dict'][0])\n",
    "# find_semantic_matches(moalmanac_new_draft['context'][0], list(synthetic_prompt_groundtruth_dict.keys())[99])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "388f563d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['BCR', 'ABL1']"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# # find_semantic_matches(moalmanac_entities_dict['biomarker'], extracted_entities_dict['biomarker'], threshold=1)\n",
    "# find_semantic_matches(moalmanac_entities_dict['cancer_type'], extracted_entities_dict['cancer_type'], threshold=.7)\n",
    "# moalmanac_entities_dict['cancer_type']\n",
    "# user_entities[\"extracted_entities_dict\"]=user_entities[\"extracted_entities_dict\"].apply(ast.literal_eval)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
